Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
BIO'2011<br />
Bio inteRn<strong>at</strong>ionaL ConVention<br />
june 27 – 30, 2011<br />
Washington DC<br />
Welcome to the <strong>French</strong> <strong>Pavilion</strong>
<strong>UBIFRANCE</strong> and the network of Trade Commissions<br />
together constitute the <strong>French</strong> government’s corpor<strong>at</strong>e<br />
intern<strong>at</strong>ional expansion support framework, and,<br />
every year, help over 13,000 companies of all sizes and<br />
from all sectors to develop their activities worldwide,<br />
thanks to the expertise of 2,500 staff based in France<br />
and in 120 countries, who oper<strong>at</strong>e through the Trade<br />
Commissions of the <strong>French</strong> Embassies, a network of<br />
press offices and numerous approved partners.<br />
<strong>UBIFRANCE</strong> and the network of Trade Commissions<br />
offer <strong>French</strong> businesses a complete range of products<br />
and support services for their expansion into foreign<br />
markets – targeted inform<strong>at</strong>ion about opportunities<br />
and major players in every sector; upd<strong>at</strong>es on changes<br />
in laws and regul<strong>at</strong>ions; d<strong>at</strong>a on intern<strong>at</strong>ional funding<br />
and invit<strong>at</strong>ions to tender; sector monitoring services;<br />
invit<strong>at</strong>ions to canvassing missions, trade fairs abroad,<br />
and partnership meetings; help with intern<strong>at</strong>ional press<br />
coverage, etc. The Agency also runs the Intern<strong>at</strong>ional<br />
Voluntary Service in Business employment scheme (VIE)<br />
for companies seeking intern<strong>at</strong>ionally mobile gradu<strong>at</strong>es.<br />
Invest in France Agency (IFA) promotes and facilit<strong>at</strong>es<br />
intern<strong>at</strong>ional investment in France. The IFA network<br />
oper<strong>at</strong>es worldwide. IFA works in partnership with<br />
regional development agencies to offer intern<strong>at</strong>ional<br />
investors business opportunities and customized<br />
services all over France. For more inform<strong>at</strong>ion, please<br />
visit www.investinfrance.org<br />
Invest in France (IFA)<br />
77 boulevard saint jacques<br />
75680 Paris Cedex 14 – France<br />
Phone : +33 1 44 87 17 17 / +33 1 40 74 73 19<br />
Fax : +33 1 40 74 73 27<br />
email : info@investinfrance.org<br />
Web site : investinfrance.org
PARTICIPANTS<br />
Partners<br />
ACCINOV ...........................................................................................6<br />
ALSACE BIOVALLEY ......................................................................6<br />
ALSACE INTERNATIONAL ................................................................7<br />
ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ..............................7<br />
ATLANPOLE BIOTHERAPIES ........................................................8<br />
AUVERGNE BIOCLUSTER .................................................................8<br />
BIOCITECH ........................................................................................9<br />
BIOPÔLE CLERMONT-LIMAGNE ......................................................9<br />
BRETAGNE INTERNATIONAL .........................................................10<br />
CANCER BIO SANTÉ ...................................................................10<br />
CANCER CAMPUS ® .........................................................................11<br />
CANCÉROPÔLE CLARA ..................................................................11<br />
CAPBIOTEK .....................................................................................12<br />
COMMUNAUTÉ URBAINE DU GRAND TOULOUSE.........................12<br />
CRITT SANTÉ BRETAGNE ...............................................................13<br />
ESSONNE CHAMBER OF COMMERCE & INDUSTRY .....................13<br />
ESSONNE SOUTH PARIS REGION ..................................................14<br />
EUROBIOMED .............................................................................14<br />
GENOPOLE ......................................................................................15<br />
LILLE EURASANTÉ .........................................................................15<br />
LYON CHAMBER OF COMMERCE & INDUSTRY .............................16<br />
LYONBIOPOLE ............................................................................16<br />
MEDICEN PARIS REGION ...........................................................17<br />
MONTPELLIER AGGLOMÉRATION ..................................................17<br />
ONLYLYON - ADERLY ......................................................................18<br />
ONLYLYON - GREATER LYON ..........................................................18<br />
PARIS CHAMBER OF COMMERCE AND INDUSTRY .......................19<br />
PARIS REGION ECONOMIC DEVELOPMENT AGENCY ....................19<br />
PROLOGUE BIOTECH - SICOVAL ....................................................20<br />
PROVENCE PROMOTION ................................................................20<br />
TEAM CÔTE D’AZUR ........................................................................21<br />
TECHNOPOLE CBS .........................................................................21<br />
UNIVERSITÉ DE LYON - LYON SCIENCE TRANSFERT ...................22<br />
<strong>French</strong> Competitiveness Cluster<br />
ComPanies<br />
ADOCIA ............................................................................................24<br />
AEPODIA..........................................................................................24<br />
AFFILOGIC .......................................................................................25<br />
ALAXIA .............................................................................................25<br />
ALIZE PHARMA ...............................................................................26<br />
ALMETIS ..........................................................................................26<br />
ALZ PROTECT..................................................................................27<br />
AMATSI ............................................................................................27<br />
ANALGESIA PARTENERSHIP ..........................................................28<br />
ANIMASCOPE ..................................................................................28<br />
ANS BIOTECH - AUVERGNE NEUROSCIENCES .............................29<br />
ARIANA PHARMACEUTICALS .........................................................29<br />
ATLANTIC BONE SCREEN ..............................................................30<br />
AVOGADRO ......................................................................................30<br />
BIOFILM CONTROL .........................................................................31<br />
BIO-MODELING SYSTEMS ..............................................................31<br />
BIOSIMS TECHNOLOGIES ...............................................................32<br />
BIOTRIAL .........................................................................................32<br />
CABINET REGIMBEAU ....................................................................33<br />
CELLECTIS BIORESEARCH ............................................................33<br />
CHELATEC .......................................................................................34<br />
CILOA...............................................................................................34<br />
CLICDATA ........................................................................................35<br />
COLCOM ..........................................................................................35<br />
DBV TECHNOLOGIES ......................................................................36
PARTICIPANTS<br />
DOMAIN THERAPEUTICS ...............................................................36<br />
ERYTECH PHARMA .........................................................................37<br />
EUROFINS OPTIMED ......................................................................37<br />
EVEON .............................................................................................38<br />
FLAMEL TECHNOLOGIES ...............................................................38<br />
GELARC ...........................................................................................39<br />
GENOWAY ........................................................................................39<br />
GENTICEL .......................................................................................40<br />
HARMONIC PHARMA ......................................................................40<br />
HELIOSBIOSCIENCES .....................................................................41<br />
HEMARINA ......................................................................................41<br />
HTL BIOTECHNOLOGY ....................................................................42<br />
ICDD ................................................................................................42<br />
IMABIOTECH ...................................................................................43<br />
IMMUNID TECHNOLOGIES .............................................................43<br />
INCELL ART ....................................................................................44<br />
INDICIA BIOTECHNOLOGY ..............................................................44<br />
INGEN BIOSCIENCES .....................................................................45<br />
INNOBIOCHIPS ...............................................................................45<br />
INSTITUT MERIEUX.........................................................................46<br />
IRIS PHARMA ..................................................................................46<br />
KAYENTIS ........................................................................................47<br />
LABORATOIRE ICARE......................................................................47<br />
LFB ..................................................................................................48<br />
MAGNISENSE ..................................................................................48<br />
MEDINCELL ....................................................................................49<br />
MEDIT ..............................................................................................49<br />
METABRAIN RESEARCH .................................................................50<br />
MILLEGEN .......................................................................................50<br />
NETRIS PHARMA ............................................................................51<br />
NEUROFIT .......................................................................................51<br />
NICOX ..............................................................................................52<br />
NOKAD ............................................................................................52<br />
NOSOPHARM ..................................................................................53<br />
NOVALIX ..........................................................................................53<br />
ONCODESIGN ..................................................................................54<br />
ONCOMEDICS .................................................................................54<br />
ONLY FOR CHILDREN PHARMACEUTICALS ..................................55<br />
OROXCELL.......................................................................................55<br />
OXELTIS ...........................................................................................56<br />
PHARMAXON...................................................................................56<br />
PHENOPRO .....................................................................................57<br />
POLYPLUS-TRANSFECTION ...........................................................57<br />
PORSOLT .........................................................................................58<br />
POXEL .............................................................................................58<br />
PRESTWICK CHEMICAL..................................................................59<br />
PROVEPHARM.................................................................................59<br />
PX’THERAPEUTICS .........................................................................60<br />
QUINTEN .........................................................................................60<br />
RHENOVIA PHARMA .......................................................................61<br />
ROOWIN ..........................................................................................61<br />
SYNTHELIS ......................................................................................62<br />
TB DRUG BOOST .............................................................................62<br />
TEXCELL .........................................................................................63<br />
TFCHEM ..........................................................................................63<br />
THERALPHA ....................................................................................64<br />
TRANSGENE ...................................................................................64<br />
TROPHOS ........................................................................................65<br />
VALYSCO ..........................................................................................65<br />
VIVALIS ............................................................................................66<br />
X’PROCHEM ....................................................................................66<br />
ZOPHIS ............................................................................................67
PARTNERS
ACCINOV<br />
321 avenue Jean Jaurès<br />
69007 LYON - FRANCE<br />
Phone: +33 6 20 72 17 67<br />
Fax: +33 4 72 70 48 29<br />
Email: bernard.mandrand@lyonbiopole.com<br />
Web site: www.accinov.com<br />
Contact: Bernard MANDRAND<br />
acCInov is an innov<strong>at</strong>ion pl<strong>at</strong>form of 6000 sq.m. in Lyon Gerland, part of Lyonbiopole’s<br />
infrastructure policy to support innov<strong>at</strong>ion. This project follows Lyonbiopôle’s Infectious<br />
Diseases Centre, open in April 2009 on the Charles Merieux campus in Lyon Gerland.<br />
The new pl<strong>at</strong>form intends to host pl<strong>at</strong>forms in pre-clinical and clinical research in<br />
biotechnology and biopharmaceuticals. This new facility will be dedic<strong>at</strong>ed to start-ups<br />
and SMBs, new or emerging, to provide services in the areas of biological analysis and<br />
biomanufacturing for the development of new health products for prevention, therapy<br />
or diagnostic. acCInov is looking for potential SMBs willing to set up their activity in<br />
Europe.<br />
ALSACE BIOVALLEY<br />
Parc d’Innov<strong>at</strong>ion<br />
9 boulevard Gonthier d’Andernach<br />
67400 ILLKIRCH - FRANCE<br />
Phone: +33 3 90 40 30 00<br />
Fax: +33 3 90 40 30 01<br />
Email: admin@alsace-biovalley.com<br />
Web site: www.alsace-biovalley.com<br />
Alsace BioValley is your ideal partner for an easy access to: Licensing opportunities;<br />
R&D collabor<strong>at</strong>ions and projects funding; Innov<strong>at</strong>ive technological pl<strong>at</strong>forms;<br />
Competitive CRO and CMO; Establishment of European subsidiaries. BioValley is also<br />
a leading trin<strong>at</strong>ional biocluster in Europe spreading over Alsace-France, South Baden-<br />
Germany, and Basel area-Switzerland.<br />
6
ALSACE INTERNATIONAL<br />
Immeuble le Sébastopol<br />
3 quai Kléber<br />
67000 STRASBOURG - FRANCE<br />
Phone: +33 3 88 24 77 68<br />
Fax: +33 3 88 24 77 77<br />
Email: p.h<strong>at</strong>esuer@alsace–intern<strong>at</strong>ional.eu<br />
Contact: P<strong>at</strong>ricia HATESUER<br />
Alsace Intern<strong>at</strong>ional is the economic development agency of the Alsace region.<br />
We accompany intern<strong>at</strong>ional companies interested in doing business in ALSACE’s<br />
BIOVALLEY, the leading trin<strong>at</strong>ional life sciences cluster in Europe.<br />
Alsace Intern<strong>at</strong>ional provides free and confidential customized services for companies<br />
interested in knowing more about doing business in Alsace or in Europe. Services<br />
include loc<strong>at</strong>ion inform<strong>at</strong>ion, grant negoti<strong>at</strong>ions, access to venture capital, business<br />
and scientific contact facilit<strong>at</strong>or, staff integr<strong>at</strong>ion. AI works in close collabor<strong>at</strong>ion with<br />
the ABV network of regional partners.<br />
AI also relies on a network of branch offices worldwide including in the United St<strong>at</strong>es,<br />
Canada, Japan, China, Poland, etc.<br />
ASSISTANCE PUBLIQUE<br />
HÔPITAUX DE PARIS<br />
228 rue du Faubourg Saint-Martin<br />
75010 PARIS - FRANCE<br />
Phone: +33 1 44 84 17 18<br />
Fax: +33 1 44 84 17 00<br />
Email: emanuelle.pascolo@sls.aphp.fr<br />
Web site: http://ottpi.aphp.fr/<br />
Contact: Emanuelle PASCOLO-REBOUILLAT<br />
AP-HP is a public health feder<strong>at</strong>ion for the Paris metropolitan area th<strong>at</strong> g<strong>at</strong>hers<br />
38 hospitals and employs more than 90 000 persons. AP-HP holds a pipeline of almost<br />
400 active p<strong>at</strong>ents in various fields: drug discovery, medical device, gene and cell<br />
therapies, genetics and diagnostics. Through its Office of Technology transfer and<br />
Industrial Partnerships (OTT&PI), AP-HP has successfully developed an active policy<br />
of technology transfer and valu<strong>at</strong>ion of the innov<strong>at</strong>ions stemming from its medical and<br />
research teams.<br />
7
ATLANPOLE<br />
BIOTHERAPIES<br />
95 route de Gachet<br />
Parc de la Chantrerie<br />
44307 NANTES Cedex 3 - FRANCE<br />
Phone: +33 2 40 25 27 20<br />
Fax: +33 2 40 25 10 88<br />
Web site: www.<strong>at</strong>lanpolebiotherapies.com<br />
Contact: Gregory BAUER<br />
For pharmaceutical companies looking for high level partners devoted to healthcare<br />
and biotech, Atlanpole Biotherapies is a cluster th<strong>at</strong> draws together a community<br />
of innov<strong>at</strong>ive companies, fundamental & clinical research organiz<strong>at</strong>ions and higher<br />
educ<strong>at</strong>ion institutions, all loc<strong>at</strong>ed in Western France. Atlanpole Biotherapies gives you<br />
access to extended skills, from biodiagnostics to biomedicine in 4 major areas: cell &<br />
gene therapy, immunology (tumor vaccin<strong>at</strong>ion and transplant<strong>at</strong>ion), biom<strong>at</strong>erials and<br />
radiopharmaceuticals.<br />
AUVERGNE BIOCLUSTER<br />
Centre Delille - Place Delille<br />
63058 CLERMOND FERRAND Cedex 1<br />
FRANCE<br />
Phone: +33 4 73 31 84 45<br />
Fax: +33 4 73 31 84 00<br />
Email: s.lopez@arde-auvergne.com<br />
Web site: www.investir-en-auvergne.com<br />
Contact: Sonia LOPEz<br />
The Regional Economic Development Agency for Auvergne objective is to structure<br />
and promote the region’s talents in biotechnologies. One main mission: to canvass<br />
successful companies in a position to develop investment projects in Auvergne and to<br />
help them set up in the region.<br />
8
BIOCITECH<br />
102 avenue Gaston Roussel<br />
93230 ROMAINVILLE - FRANCE<br />
Phone: +33 1 49 91 31 05<br />
Fax: +33 1 49 91 31 03<br />
Email: jf.boussard@biocitech.com<br />
Web site: www.biocitech.com<br />
Contact: Jean-François BOUSSARD<br />
The Biocitech technology park for life sciences, loc<strong>at</strong>ed on the outskirts of Paris,<br />
offers a world-class environment and services for the development of biotechnology,<br />
biopharmaceutical and fine chemical companies. It is priv<strong>at</strong>ely owned and provides<br />
secure premises and comprehensive facilities based on the l<strong>at</strong>est technology.<br />
Companies can use one or many of the services offered. These include offices,<br />
labor<strong>at</strong>ories and a range of technical and scientific services. Companies already<br />
established <strong>at</strong> Biocitech represent a wide variety of complementary disciplines and<br />
many are working on collabor<strong>at</strong>ive projects. Biocitech is strongly involved in the<br />
development of Paris Region Bio cluster. Along with other organiz<strong>at</strong>ions in the Ilede-France<br />
region around Paris, Biocitech plays a key role in the Medicen Paris Region<br />
network.<br />
BIOPÔLE<br />
CLERMONT-LIMAGNE<br />
Biopôle Clermont-Limagne<br />
63360 SAINT-BEAUzIRE - FRANCE<br />
Phone: +33 4 73 64 43 43<br />
Fax: +33 4 73 64 43 44<br />
Email:<br />
herve.prevoteau@biopole-clermont.com<br />
Web site: www.biopole-clermont.com<br />
Contact: Hérvé PREVOTEAU<br />
The Biopôle Clermont-Limagne was one of the first European technology parks fully<br />
dedic<strong>at</strong>ed to hosting and supporting bio-tech businesses.<br />
It offers bio entrepreneurs an extensive range of tools aimed <strong>at</strong> enhancing business<br />
cre<strong>at</strong>ion and development: cre<strong>at</strong>ion support, networks and funding, accommod<strong>at</strong>ion<br />
and services.<br />
The Biopôle Clermont-Limagne is an interactive pl<strong>at</strong>form for professionals of the<br />
life sciences sector. It encourages collabor<strong>at</strong>ive networking between companies,<br />
research centers, professional associ<strong>at</strong>ions, sciences parks and economic development<br />
organiz<strong>at</strong>ions.<br />
9
BRETAGNE<br />
INTERNATIONAL<br />
Parc Eolys - 16 C rue Jouanet - CS 20834<br />
35708 RENNES Cedex 7 - FRANCE<br />
Phone: +33 2 99 25 04 04<br />
Fax: +33 2 99 25 04 00<br />
Email:<br />
bretagne@bretagne-intern<strong>at</strong>ional.com<br />
Contact: Adrienne GENTIL<br />
Bretagne Intern<strong>at</strong>ional is a non-profit associ<strong>at</strong>ion commissioned by the Regional<br />
Government of Bretagne (Western part of France) to:<br />
• assist Breton companies in their intern<strong>at</strong>ional development<br />
• identify projects of investment in Bretagne and support foreign investors.<br />
Relying on our excellent knowledge of companies ‘ know-how and economic structure<br />
in our region, we can assist YOU with free and confidential assistance through<br />
the different stages of your project to cre<strong>at</strong>e or acquire a company in Bretagne:<br />
d<strong>at</strong>a collection, identific<strong>at</strong>ion of and introduction to potential partners, proposals of<br />
loc<strong>at</strong>ions, assistance before, during and after the install<strong>at</strong>ion…<br />
CANCER BIO SANTÉ<br />
5 avenue Irène Joliot-Curie<br />
31100 TOULOUSE - FRANCE<br />
Phone: +33 5 34 25 50 40<br />
Fax: +33 5 34 25 50 41<br />
Email: contact@cancerbiosante.fr<br />
Web site: www.cancerbiosante.fr<br />
Contact: Céline BEDJA<br />
Cancer-Bio-Santé Cluster, loc<strong>at</strong>ed in Toulouse, is the <strong>French</strong> cluster in France<br />
fully dedic<strong>at</strong>ed to the fight against Cancer, throughout a broad continuum approach<br />
involving prevention, diagnostics, therapeutics and p<strong>at</strong>ient monitoring. CBS supports<br />
companies from the Midi Pyrénées and Limousin regions, which develop innov<strong>at</strong>ive<br />
products in the fields of food & Health, Diagnostics, Biomarkers, Nanotechnologies,<br />
Medical Devices, Immunotherapy, Therapeutics, Bioproduction, Biotechnologies and<br />
Telemedicine.<br />
10
CANCER CAMPUS ®<br />
Espace Maurice Tubiana<br />
114 rue Edouard Vaillant<br />
94805 VILLEJUIF - FRANCE<br />
Phone: +33 1 42 11 67 73<br />
Fax: +33 1 42 11 53 11<br />
Email: valerie.helin@cancer-campus.com<br />
Web site: www.cancer-campus.com<br />
Contact: Valérie HELIN<br />
Cancer Campus is the Paris biocluster dedic<strong>at</strong>ed to cancer innov<strong>at</strong>ion and<br />
brings together, on a specific <strong>at</strong>tracting place, next door to the largest European<br />
comprehensive cancer center (Institut Gustave Roussy), all the first-r<strong>at</strong>e skills to<br />
reach the best of innov<strong>at</strong>ion in all aspects of oncology. Our first building will open in<br />
September 2011 and will be dedic<strong>at</strong>ed to biotechs which will have access to the st<strong>at</strong>eof-the-art<br />
technological pl<strong>at</strong>forms of the Institut Gustave Roussy and of its academic<br />
and clinical partners.<br />
CANCÉROPÔLE CLARA<br />
60 avenue Rockefeller<br />
69008 LYON - FRANCE<br />
Phone: +33 4 37 90 17 15<br />
Fax: +33 4 37 90 27 03<br />
Email: llevy@canceropole-clara.com<br />
Web site: www.canceropole-clara.com<br />
Contact: Laurent LEVY<br />
Cre<strong>at</strong>ed in 2003 by the <strong>French</strong> N<strong>at</strong>ional Cancer Institute (INCa), the Lyon Auvergne<br />
Rhône-Alpes Cancer cluster (CLARA) aims to develop research in oncology in Rhône-<br />
Alpes and Auvergne by associ<strong>at</strong>ing academic, clinical and industrial strengths in order<br />
to develop a regional, n<strong>at</strong>ional and intern<strong>at</strong>ional str<strong>at</strong>egy in the fight against Cancer.<br />
CLARA contributes to the implement<strong>at</strong>ion of partnerships between industrials,<br />
academic and clinical research labor<strong>at</strong>ories to foster technological transfers for the<br />
benefit of p<strong>at</strong>ients.<br />
11
CAPBIOTEK<br />
18 place de la Gare<br />
35000 RENNES - FRANCE<br />
Phone: +33 2 99 67 71 15<br />
Email: bmonks@bretagne-innov<strong>at</strong>ion.fr<br />
Web site: www.capbiotek.fr<br />
Contact: Brian MONKS<br />
Capbiotek, the Bretagne biocluster where n<strong>at</strong>ure meets innov<strong>at</strong>ion.<br />
Thanks to Bretagne’s exceptional marine and agricultural resources, a unique<br />
greentech environment, a world-class agrifood industry, high-level technological<br />
expertise and academic firepower, Bretagne has become a major player in biotech in<br />
France and in Europe as a whole.<br />
COMMUNAUTÉ URBAINE<br />
DU GRAND TOULOUSE<br />
Le Grand Toulouse<br />
Department of Economic Development<br />
6 rue Renée Leduc - BP 35821<br />
31505 TOULOUSE Cedex 5 - FRANCE<br />
Phone: +33 5 81 91 72 11<br />
Fax: +33 5 81 91 72 03<br />
Email: odile.rouillard@grandtoulouse.fr<br />
Web site: www.grandtoulouse.fr<br />
Contact: Odile ROUILLARD<br />
The “Grand Toulouse” Urban community brings together 37 towns and 703 000<br />
inhabitants. Toulouse is the 4 th largest city in France and one of the most <strong>at</strong>tractive<br />
cities in Europe. The “Grand Toulouse” Toulouse is hosting 3 competitiveness clusters,<br />
Aerospace Valley, Cancer Bio Health, Agrimip Innov<strong>at</strong>ion and develops majors projects.<br />
Toulouse is one of the leading regions in Europe for research and development<br />
- 500 labor<strong>at</strong>ories - 20 000 employees in research, 100 000 students - with an<br />
ambitious project, The Toulouse Cancéropôle, a campus dedic<strong>at</strong>ed to the fight against<br />
cancer, combining the strength of innov<strong>at</strong>ive public and priv<strong>at</strong>e sector.<br />
12
CRITT SANTÉ BRETAGNE<br />
2 avenue du Pr Léon Bernard - CS 34317<br />
35043 RENNES Cedex - FRANCE<br />
Phone: +33 2 23 23 45 81<br />
Fax: +33 2 23 23 45 86<br />
Email: jocelyne.leseyec@critt-sante.fr<br />
or contact@critt-sante.fr<br />
Web site: www.critt-sante.fr<br />
Contact: Jocelyne LE SEYEC<br />
CRITT Santé Bretagne works for research units and companies involved in the R&D of<br />
health-care applic<strong>at</strong>ions in Western France. Our missions are to develop and support<br />
partnerships, to provide technological assistance, to assist project leaders and to<br />
promote development of SMEs.<br />
Our fields of expertise include:<br />
1) Medical devices, medical imaging, health technologies<br />
2) Nutrition for human health and<br />
3) Biotechnology, drug development, new therapies. We particip<strong>at</strong>e to Capbiotek,<br />
the Bretagne biocluster.<br />
ESSONNE CHAMBER OF<br />
COMMERCE & INDUSTRY<br />
2 cours Monseigneur Roméro<br />
BP 135 - 91004 EVRY - FRANCE<br />
Phone: +33 1 60 79 90 74<br />
Fax: +33 1 60 79 90 71<br />
Email:<br />
rel<strong>at</strong>ions.intern<strong>at</strong>ionales@essonne.cci.fr<br />
Web site: www.essonne.cci.fr<br />
Contact: Marianne SASSERANT<br />
The Essonne Chamber of Commerce & Industry represents the general interests<br />
of Industry & commerce, promotes the companies of its district localy as well as<br />
intern<strong>at</strong>ionally. Through the Boston office Hubtech21, it provides specialized services<br />
in helping technology companies establish & grow their business in trans<strong>at</strong>lantic<br />
markets efficiently. We provide clients in the Life Sciences with a range of customized<br />
service solutions, from pre-market prospecting and logistics services, to full<br />
oper<strong>at</strong>ional support (market intelligence, Development str<strong>at</strong>egies, sales support…).<br />
BOSTON OFFICE: One Broadway 14 th floor-Cambrige, MA 02142- USA - Tel:+ 617 583<br />
1350 hubtech21@hubtech21.com<br />
13
ESSONNE<br />
SOUTH PARIS REGION<br />
6 Cours Monseigneur Roméro<br />
91025 EVRY - FRANCE<br />
Phone: +33 1 69 91 42 56<br />
Fax: +33 1 69 91 17 81<br />
Email: caroline.mercier@essonnedeveloppement.com<br />
Web site: www.essonne-developpement.com<br />
Contact: Caroline MERCIER<br />
You want to: Grow your sales in EU and reach <strong>French</strong> and European customers? Form<br />
a EU subsidiary within deadline and budget? Recruit key staff? Get in touch with<br />
str<strong>at</strong>egic partners and service providers?<br />
We can help you to: Get tailor-made services to solve your development problems;<br />
Save time: a dedic<strong>at</strong>ed manager is in charge of your whole project. Save money:<br />
Essonne services are free of charge and confidential; Lower risks in setting up in<br />
France: Essonne makes you benefit from its networks to start oper<strong>at</strong>ions as efficiently<br />
as possible.<br />
EUROBIOMED<br />
C/ CMCI - 2 rue Henri Barbusse<br />
13001 MARSEILLE - FRANCE<br />
Phone: +33 4 91 13 74 65<br />
Fax: +33 4 91 13 74 66<br />
Email: contact@eurobiomed.org<br />
Web site: www.eurobiomed.org<br />
Contact: Emilie ROYèRE<br />
Eurobiomed is accredited by the french government as a competitiveness<br />
cluster. Eurobiomed feder<strong>at</strong>es more than 400 healthcare stakeholders along the<br />
Mediterranean border in the south of France. Our main missions are to develop and<br />
feder<strong>at</strong>e the network in order to boost the development of partnerships; to provide<br />
business support to companies via the implement<strong>at</strong>ion of services, tools and access<br />
to funding; to highlight the excellence of both academic and industrial healthcare<br />
research performed in the South of France; to ease the access to public fundings for<br />
collabor<strong>at</strong>ive R&D projects.<br />
14
GENOPOLE<br />
GENOPOLE Campus 1<br />
5 rue Henri Desbrueres<br />
91030 EVRY - FRANCE<br />
Phone: +33 1 60 87 83 12<br />
Fax: +33 1 60 87 83 01<br />
Email: gabriel.mergui@genopole.fr<br />
Contact: Gabriel MERGUI<br />
GENOPOLE is France’s leading biopark dedic<strong>at</strong>ed to biotech & genetics research. It<br />
brings together priv<strong>at</strong>e and academic labs, biotech companies and higher educ<strong>at</strong>ion<br />
facilities (University of Evry Val d’Essonne) on a 90,000 sqm site. With 20 research labs<br />
and a portfolio of over 70 biotech firms, therapeutic innov<strong>at</strong>ion is a key concern for<br />
Genopole stakeholders. Genopole’s objective is to reinforce technology transfer to the<br />
industrial sector; cre<strong>at</strong>e and m<strong>at</strong>ure biotech companies.<br />
LILLE EURASANTÉ<br />
Parc Eurasanté<br />
310 avenue Eugène Avinée<br />
59120 LOOS - FRANCE<br />
Phone: +33 3 28 55 90 60<br />
Fax: +33 3 28 55 90 61<br />
Email: crondel@eurasante.com<br />
Web site: www.eurasante.com<br />
Contact: Christelle RONDEL<br />
Eurasanté, the Economic Development Agency dedic<strong>at</strong>ed to healthcare, nutrition and<br />
biotech activities in Northern France, promotes the Lille cluster and the Bio Business<br />
Park where 120 health, nutrition & biotech companies are settled within the largest<br />
European university hospital complex. We assist firms in setting-up in Northern<br />
France.<br />
15
LYON CHAMBER OF<br />
COMMERCE AND INDUSTRY<br />
Place de la Bourse<br />
69289 LYON Cedex 02 - FRANCE<br />
Phone: +33 4 72 40 57 28<br />
Fax: +33 4 72 40 57 61<br />
Email: hours@lyon.cci.fr<br />
Web site: www.lyon.cci.fr<br />
Contact: Julie-Capucine HOURS ROUSSILLE<br />
The Lyon Chamber of Commerce and Industry is a public organis<strong>at</strong>ion. Its mission<br />
is to:<br />
• lobby the public authorities in the interest of companies and retailers in its district<br />
• promote Lyon’s advantages, <strong>at</strong>tract inward investment and newcomer businesses<br />
• assist companies, retailers and service businesses in every stage of their<br />
development<br />
• build and manage facilities needed for local economic development.<br />
The Lyon CCI’s intern<strong>at</strong>ional department provides local <strong>French</strong> companies with<br />
intern<strong>at</strong>ional development consulting by giving economic, str<strong>at</strong>egic, tax and legal<br />
advice for integr<strong>at</strong>ing foreign markets.<br />
LYONBIOPOLE<br />
Bâtiment Domilyon<br />
321 avenue Jean Jaurès<br />
69007 LYON - FRANCE<br />
Phone: +33 4 72 76 53 30<br />
Fax: +33 4 72 70 48 29<br />
Email: isabelle.scarabin@lyonbiopole.com<br />
Web site: www.lyonbiopole.com<br />
Contact: Isabelle SCARABIN<br />
Lyonbiopole is a <strong>French</strong> BIO Cluster loc<strong>at</strong>ed in the Rhone-Alpes Region (Lyon-<br />
Grenoble area) and focused on human/animal infectious diseases, immune disorders<br />
and cancers.<br />
Lyonbiopole is your str<strong>at</strong>egic partner in France to: - Develop your network and identify<br />
str<strong>at</strong>egic partners – Innov<strong>at</strong>e and set-up R&D projects - Gain access to public and<br />
priv<strong>at</strong>e funds - Settle your activity in fully equipped pl<strong>at</strong>form of excellence (BSL2/BSL3<br />
Labs, dedic<strong>at</strong>ed bioproduction & bioanalyses facilities, etc.).<br />
16
MEDICEN PARIS REGION<br />
6 rue Alexandre Cabanel<br />
75015 PARIS - FRANCE<br />
Phone: +33 1 44 49 30 00<br />
Fax: +33 1 44 49 30 05<br />
Email: medicen@medicen.org<br />
Web site: www.medicen.org<br />
Contact: François CHEVILLARD<br />
Medicen Paris Region is a cluster which unites all key life science and healthcare<br />
players in the Paris metropolitan area, France.The cluster’s top priorities are to<br />
cre<strong>at</strong>e a cluster environment fostering the development of the health sector in<br />
the Paris Region, to promote growth of its companies and to develop n<strong>at</strong>ional and<br />
intern<strong>at</strong>ional partnerships to increase the cluster’s and the Paris Region’s notoriety<br />
and <strong>at</strong>tractiveness.<br />
The Medicen Paris Region’s R&D str<strong>at</strong>egy is based on: transl<strong>at</strong>ional medicine,<br />
biological tools for industrial use and bio-therapeutic products, biodigital technology<br />
(bio-computing, integr<strong>at</strong>ion and modelling, e-health, brain-machine interface<br />
technology).<br />
MONTPELLIER<br />
AGGLOMÉRATION<br />
50 place zeus – CS 39556<br />
34961 MONTPELLIER Cedex 2 - FRANCE<br />
Phone: +33 4 67 13 61 20<br />
Fax: +33 4 67 13 61 10<br />
Email: t.asteriou@montpellier-agglo.com<br />
Web site: www.montpellier-technopole.com<br />
Contact: Trias ASTERIOU<br />
The life sciences sector is one of the driving factors in the Montpellier (France) economy.<br />
Montpellier is a city with a long tradition in medicine with more than 120 public<br />
sector and priv<strong>at</strong>e research labor<strong>at</strong>ories, several leading intern<strong>at</strong>ional companies<br />
(sanofi aventis, BioRad, Horiba Medical, Bausch & Lomb…) and an important tissue<br />
of innov<strong>at</strong>ive SMEs. Euromédecine Biopôle, 21,000 sq.m of offices and labor<strong>at</strong>ories<br />
dedic<strong>at</strong>ed to life sciences companies (10,500 sq.m already delivered). Montpellier<br />
Intern<strong>at</strong>ional Business Incub<strong>at</strong>or: A 3,500 m² building for foreign companies with soft<br />
landings services.<br />
17
ONLYLYON ADERLY<br />
Place de la Bourse<br />
69002 LYON - FRANCE<br />
Phone: +33 4 72 40 81 98<br />
Email: delumley@aderly.com<br />
Web site: www.aderly.com<br />
Contact: Thierry de LUMLEY<br />
ADERLY’s key strength is to provide a customized business development service. This<br />
includes one-to-one meetings with potential customers, R&D partners and key opinion<br />
leaders, as well as lawyers, accountants, public investors, venture capitalists and<br />
business angels. In Lyon, join leaders such as Genzyme, Biomérieux, Merial, Becton<br />
Dickinson, Mylan, Covidien, Sanofi-Pasteur, Merck Serono, Integra Life Sciences,<br />
Baxter, Abbott Pharma and Olympus Biotechnology, along with other companies who<br />
have been assisted by ADERLY in the boosting of their European business: Singulex,<br />
Oncotherapy Sciences, Prediction Sciences, CellSeed and more.<br />
ONLYLYON<br />
GREATER LYON<br />
20 rue du lac - BP 3103<br />
69399 LYON Cedex 03 - FRANCE<br />
Phone: +33 4 78 63 42 31<br />
Fax: +33 4 26 99 38 74<br />
Email: clab<strong>at</strong>@grandlyon.org<br />
Web site:<br />
www.entreprendre @grandlyon.org<br />
Contact: Clémence LABAT<br />
Through its partnership-based approach, Gre<strong>at</strong>er Lyon <strong>at</strong>tracts year after year more<br />
investors and intern<strong>at</strong>ional business leaders. The skills of the institutional partners<br />
of the Life Sciences are leveraged to <strong>at</strong>tract talent, support innov<strong>at</strong>ion and help<br />
companies start up and develop.<br />
Gre<strong>at</strong>er Lyon financially supports the actions of the Lyonbiopôle competitive cluster<br />
and of the Cancer Center CLARA research cluster, as well as key projects for the urban<br />
area in connection with the Life Sciences.<br />
18
PARIS CHAMBER OF COMMERCE<br />
AND INDUSTRY<br />
Bourse de Commerce<br />
2 rue de Viarmes<br />
75001 PARIS - FRANCE<br />
Phone: +33 1 55 65 35 13<br />
Fax: +33 1 55 65 35 85<br />
Email: ipottier@ccip.fr<br />
Web site: www.intern<strong>at</strong>ional.ccip.fr<br />
Contact: Isabelle POTTIER<br />
Paris area is a leading region as far as Life Sciences are concerned. The Paris Chamber<br />
of Commerce and Industry provides customized services for companies interested in<br />
doing business <strong>at</strong> an intern<strong>at</strong>ional level. We assist them in finding potential partners<br />
and opportunities abroad.<br />
The Paris Chamber of Commerce and Industry strongly supports Life Sciences as a<br />
leading industry. We work with the Paris Region Life Sciences cluster: Medicen Paris<br />
Region.<br />
PARIS REGION ECONOMIC<br />
DEVELOPMENT AGENCY<br />
3 rue des Saussaies<br />
75008 PARIS - FRANCE<br />
Phone: +33 1 58 18 69 00<br />
Fax: +33 1 58 18 69 71<br />
Email: lcurti@paris-region.com<br />
Web site: www.paris-region.com<br />
Contact: Laurence CURTI<br />
If you are interested in doing business in Paris Region, Paris Region Economic<br />
Development Agency is here to help you. With a core of recognized skills and an<br />
effective network of experience, the agency’s mission is to support your projects:<br />
informing you (tax<strong>at</strong>ion issues, purchase and rental costs…), advising you (setting up<br />
your new company, loc<strong>at</strong>ion offices…), and supporting you (setting up technology and<br />
marketing partnerships, support for exp<strong>at</strong>ri<strong>at</strong>es…).<br />
19
PROVENCE PROMOTION<br />
Les Docks Atrium 10.5<br />
10 place de la Joliette<br />
13002 MARSEILLE - FRANCE<br />
Phone: +33 4 96 11 60 00<br />
Fax: +33 4 96 11 60 11<br />
Email: m.vis@provence-promotion.fr<br />
Web site: www.theprovencepartnership.com<br />
Contact: M<strong>at</strong>thieu VIS<br />
Provence Promotion is the Official Inward Investment agency of Marseille-Provence<br />
area, South of France.<br />
We assist free of charge companies reloc<strong>at</strong>e and/or develop their business in our<br />
Mediterranean region, which has become a str<strong>at</strong>egic destin<strong>at</strong>ion for biotechnology<br />
companies.<br />
Provence hosts worldwide known academic labor<strong>at</strong>ories like the Luminy Immunology<br />
centre CIML, the infectious disease University Hospital Institute led by Pr Raoult, or<br />
the oncology research institute of Paoli-Calmettes, one of France’s most concentr<strong>at</strong>ed<br />
networks of hospital/university structures with important drug development activities,<br />
as well as leading firms such as Inn<strong>at</strong>e Pharma, Ipsogen, Supersonic Imagine,<br />
Provepharm, Trophos…<br />
The Provence Partnership is your unique partner for building and growing your<br />
business in Provence.<br />
PROLOGUE BIOTECH<br />
SICOVAL<br />
Rue Pierre et Marie Curie - BP 28262<br />
31682 LABEGE Cedex - FRANCE<br />
Phone: +33 5 61 28 70 00<br />
Fax: +33 5 61 28 70 01<br />
Email: prologue.biotech@sicoval.fr<br />
Web site: www.sicoval.fr<br />
Prologue Biotech is a life science company incub<strong>at</strong>or th<strong>at</strong> currently hosts and supports<br />
9 incorpor<strong>at</strong>ed companies (Ambiotis, Genticel, Cerenis Therapeutics, Antabio, Synelvia,<br />
Icelltis, Physiogenex, Urosphere, Vectalys). In the heart of Toulouse-Labege-Innopole<br />
biopark, Prologue Biotech offers tailored facilities (1000 M 2 labor<strong>at</strong>ories, 250 m 2 offices),<br />
services (animal facility, washing area, on-line scientific document<strong>at</strong>ion, 4°C and<br />
37°C stores, etc.), business development guidance and administr<strong>at</strong>ive support by an<br />
experienced team, and privileged access to available and upcoming biotech buildings.<br />
20
TEAM COTE D’AZUR<br />
400 Promenade des Anglais - BP 3185<br />
06204 NICE Cedex 3 - FRANCE<br />
Phone: +33 4 92 17 51 85<br />
Fax: +33 4 93 80 05 76<br />
Email: cjacquet@teamcotedazur.fr<br />
Web site: www.investincotedazur.com<br />
Contact: Céline JACQUET<br />
Team Côte d’Azur is the Côte d’Azur economic development agency.<br />
Team Côte d’Azur provides companies with assistance rel<strong>at</strong>ed to a precise evalu<strong>at</strong>ion<br />
of wh<strong>at</strong> Nice and Sophia Antipolis science and technology park can offer with regard to<br />
your investment project, free and confidential assistance in preparing your setting-up<br />
file (feasibility study, identific<strong>at</strong>ion and follow-up of eligible financial support, transfer<br />
of teams to the area, essential networking, etc.)<br />
TECHNOPOLE-CBS<br />
Hôtel d’entreprises<br />
Parc d’activités des Saules<br />
27100 VAL DE REUIL - FRANCE<br />
Phone: +33 2 32 25 59 59<br />
Fax: +33 2 32 25 59 60<br />
Email: pbrottier@technopole-cbs.com<br />
Web site: www.technopole-cbs.com<br />
Contact: Philippe BROTTIER<br />
Support and network the stakeholders in the Chemistry-Biology-Health industry:<br />
Develop discussions and collabor<strong>at</strong>ive undertakings between public research and<br />
industry oper<strong>at</strong>ors in a wide range of fields; Foster the cre<strong>at</strong>ion of innov<strong>at</strong>ive activities<br />
in the region by identifying business cre<strong>at</strong>ion projects from academic research;<br />
Promote Haute-Normandie by publicising the available research potential in the<br />
region, the welcome services <strong>at</strong> industry specific business parks and the industrial<br />
environment, <strong>at</strong> conferences, trade fairs and other events.<br />
21
UNIVERSITÉ DE LYON<br />
LYON SCIENCE TRANSFERT<br />
37 rue du Repos<br />
69361 LYON - FRANCE<br />
Phone: +33 6 82 90 86 18<br />
Fax: +33 4 37 37 26 71<br />
Email: sandrine.carteau@universite-lyon.fr<br />
Web site: www.universite-lyon.fr/lst<br />
Contacts: Sandrine CARTEAU<br />
Christian MALLY<br />
Université de Lyon is a feder<strong>at</strong>ion of 18 Higher Educ<strong>at</strong>ion and research Institutes.<br />
It is strong of 230 research labor<strong>at</strong>ories, 120000 students, 5000 PhD students and<br />
11500 researchers. The Technology Transfer Office, named Lyon Science Transfert<br />
(LST), supports the Université de Lyon by transferring basic research discoveries<br />
made in the labor<strong>at</strong>ories to the marketplace for commercial development. Lyon<br />
Science Transfert offers numerous technologies on drug discovery, diagnostic, vaccine<br />
production, etc.<br />
22
COMPANIES
ADOCIA<br />
115 avenue Lacassagne<br />
69003 LYON - FRANCE<br />
Phone: +33 4 72 610 610<br />
Fax: +33 4 72 36 39 67<br />
Email: o.soula@adocia.com<br />
Web site: www.adocia.com<br />
Contact: Olivier SOULA<br />
Adocia is a protein delivery company. Its proprietary innov<strong>at</strong>ive technology<br />
BioChaperone ® has been applied to growth factors for regener<strong>at</strong>ive medicine and<br />
to insulin and monoclonal antibodies for chronic diseases. Adocia has completed<br />
successfully a phase I for fast-acting human insulin and is currently evalu<strong>at</strong>ing a<br />
spray on 200 p<strong>at</strong>ients suffering from diabetic foot ulcer. Up to now Adocia has raised<br />
28M€ and is collabor<strong>at</strong>ing with 3 pharmaceutical companies.<br />
AEPODIA<br />
La Grande Arche - Paroi Nord<br />
92044 PARIS-LA DÉFENSE - FRANCE<br />
Phone: +33 1 40 90 30 14<br />
Email: info@aepodia.com<br />
Web site: www.aepodia.com<br />
Contact: Stéphanie ALVAREz LOUzAN<br />
Aepodia is experienced and specialized in Early Phase Clinical Development<br />
and Clinical Pharmacology studies. This strong pharmacological, scientific and<br />
study design background is a gre<strong>at</strong> asset to make well balanced (value/cost/time)<br />
recommend<strong>at</strong>ions regarding potential studies to be done in view of the new legisl<strong>at</strong>ion<br />
for health and nutrition claims. In collabor<strong>at</strong>ion with you, Aepodia provide ad hoc<br />
services like coordin<strong>at</strong>ion and monitoring of your study, st<strong>at</strong>istical support, prepar<strong>at</strong>ion<br />
and writing of clinical study protocols and lastly scientific reports and public<strong>at</strong>ions to<br />
support the claim or p<strong>at</strong>ent.<br />
24
AFFILOGIC<br />
c/o UMR 6204<br />
Faculté des Sciences<br />
2 rue de la Houssinière<br />
44000 NANTES - FRANCE<br />
Phone: +33 6 25 80 73 65<br />
Email: olivier@affilogic.com<br />
Web site: www.affilogic.com<br />
Contact: Olivier KITTEN<br />
Affilogic develops custom affinity ligands for bioprocessing, analytics, diagnostics &<br />
therapeutic applic<strong>at</strong>ions.<br />
Affilogic ligands, a.k.a. Nanofitins, are highly stable, easy to manufacture and perform<br />
like mAbs in selected applic<strong>at</strong>ions.<br />
The company is providing custom development of specific Nanofitins and is looking for<br />
partners to co-develop applic<strong>at</strong>ions in Point of Care.<br />
ALAXIA<br />
3-11 rue de la Perlerie<br />
69120 Vaulx en Velin - FRANCE<br />
Phone: +33 4 72 81 09 26<br />
Fax: +33 4 78 41 17 19<br />
Email: philippe.bordeau@bioalaxia.eu<br />
Web site: www.alaxia-pharma.eu<br />
Contact: Philippe BORDEAU<br />
Alaxia, a drug discovery company, develops airway therapeutic solutions for respir<strong>at</strong>ory<br />
diseases based on its own peroxidase pl<strong>at</strong>e form. Its Meveol product, 1 st product<br />
exiting the pipeline, has been recognized Orphan medicinal product for cystic fibrosis<br />
condition by both EMA & FDA. Meveol is both an antimicrobial and anti-inflamm<strong>at</strong>ory<br />
product, targeting to kills bacteria, including antibiotic resistant strains and to<br />
compens<strong>at</strong>e inn<strong>at</strong>e lung defense system. Seeking for COPD, URTI, LRTI partnership.<br />
25
ALIZÉ PHARMA<br />
15 Chemin du Saquin<br />
Espace Européen - BAT G<br />
69130 ECULLY - FRANCE<br />
Phone: +33 4 72 18 94 28<br />
Fax: +33 4 78 33 36 29<br />
Email: tabrib<strong>at</strong>@alz-pharma.com<br />
vwesley@alz-pharma.com<br />
Web site: www-alz-pharma.com<br />
Contact: Valérie WESLEY<br />
The Alizé Pharma Group is specialized in the development of innov<strong>at</strong>ive<br />
biopharmaceuticals for the tre<strong>at</strong>ment of metabolic diseases and cancer. Its<br />
management is made up of a team of drug development experts and a board of<br />
directors offering wide intern<strong>at</strong>ional experience. The two main products currently in<br />
development include a ghrelin-derived peptide targeting type II diabetes and other<br />
cardiovascular risks, and a PEGyl<strong>at</strong>ed recombinant L-asparaginase for the tre<strong>at</strong>ment<br />
of acute lymphoblastic leukemia.<br />
ALMETIS<br />
4 rue Boussingault<br />
67000 STRASBOURG - FRANCE<br />
Phone: +33 3 68 85 31 77<br />
Email: contact@almetisbio.com<br />
Web site: www.almetisbio.com<br />
Contact: Marjorie SIDHOUM<br />
Almetis is dedic<strong>at</strong>ed to the discovery and the development of innov<strong>at</strong>ive metal-based<br />
therapeutics in oncology up to proof of concept in man. Our expertise is unique on<br />
organometallic drugs th<strong>at</strong> have demonstr<strong>at</strong>ed anticancer properties answering to<br />
usual drawbacks of chemotherapies and constituting a new class of anticancer drugs.<br />
Our mission is to provide therapeutic solutions to unmet medical needs via innov<strong>at</strong>ive<br />
tre<strong>at</strong>ment triggering specific mechanism. Almetis’ pipeline g<strong>at</strong>hers new chemical<br />
entities from hits to preclinical candid<strong>at</strong>es and is open to develop collabor<strong>at</strong>ive<br />
programs with partners.<br />
26
ALZPROTECT<br />
70 rue du Dr Yersin<br />
59120 LOOS - FRANCE<br />
Phone: +33 3 28 55 50 51<br />
Fax: +33 3 62 02 56 40<br />
Email: contact@alzprotect.com<br />
Web site: www.alzprotect.com<br />
Contact: P. VERWAERDE<br />
Alzprotect is a startup biopharmaceutical company developing small molecule drug for<br />
neurodegener<strong>at</strong>ive diseases. Its lead product, AZP2006, an anti Alzheimer candid<strong>at</strong>e<br />
drug, will enter clinical phase 1 by the end of 2011. Animal proof of concept studies<br />
have shown its unique effect on both APP and Tau p<strong>at</strong>hologies. Alzprotect is developing<br />
in parallel several small molecules against neurodegener<strong>at</strong>ive diseases.<br />
AMATSI<br />
17 Parc des Vautes<br />
34980 SAINT GELY DU FESC - FRANCE<br />
Phone: +33 4 99 58 35 86<br />
Fax: +33 4 99 58 38 61<br />
Email: l.benedicto@am<strong>at</strong>si.com<br />
Web site: www.am<strong>at</strong>si.com<br />
Contact: Lorie BENEDICTO<br />
AMATSI, loc<strong>at</strong>ed <strong>at</strong> Montpellier and Toulouse in France and Cambridge in the USA,<br />
is a Contract Development and Manufacturing Organiz<strong>at</strong>ion (CDMO) specializing in<br />
drug development services. With its strong team of 175 staff (including AVOGADRO’s<br />
people), AMATSI offers expert pharmaceutical development and clinical manufacturing<br />
services to Biotech & Pharmaceutical companies with a specific support for orphan<br />
and paedi<strong>at</strong>ric drug development. Range of expertise: formul<strong>at</strong>ion & analytical<br />
development, PK-ADME studies, bioanalysis, QC, clinical supplies manufacturing,<br />
packaging, storage and logistics, ICH stability study, regul<strong>at</strong>ory & CMC support.<br />
27
ANALGESIA<br />
PARTNERSHIP<br />
Labor<strong>at</strong>oire de Pharmacologie Médicale,<br />
Faculté de Médecine<br />
28 place Henri Dunant<br />
63000 CLERMONT-FERRAND - FRANCE<br />
Phone: +33 4 73 17 82 02<br />
Fax: +33 4 73 27 46 21<br />
Email: contact@AnalgesiaPartnership.com<br />
Web site: www.AnalgesiaPartnership.com<br />
Contact: Alice CORTEVAL<br />
Analgesia Partnership was founded in 2008 as a result of the outstanding dynamism<br />
of academics and businesses driven on the same idea: fostering the bench 1 bedside<br />
Continuum in Pain Innov<strong>at</strong>ion.<br />
This One-Stop-Shop solution offers a pl<strong>at</strong>form of integr<strong>at</strong>ed services focused on pain<br />
profiling and proposes “à la carte” services, custom-tailored for your project and<br />
flexible to adapt to your results.<br />
Academic and priv<strong>at</strong>e experts bringing together their cultures towards innov<strong>at</strong>ion, will<br />
provide you with comprehensive and complementary services from drug discovery to<br />
clinics.<br />
ANIMASCOPE<br />
zA Eurekalp<br />
38660 ST VINCENT DE MERCUzE<br />
FRANCE<br />
Phone: +33 4 76 97 94 87<br />
Fax: +33 9 55 75 39 11 09<br />
Email: d.christiaen@animascope.eu<br />
Web site: www.animascope.eu<br />
Contact: Daniel CHRISTIAEN<br />
Animascope offers customized contract services for multi-modality biomedical<br />
imaging in vivo: protocol design, image acquisition, image processing, image analysis,<br />
reporting. We assist in model sourcing and pre-conditioning. Imaging is suitable for<br />
discovery research, to bridge the gap between preclinical and clinical research, for<br />
phenotyping, model or biomarker valid<strong>at</strong>ion, biodistribution studies, as well as to<br />
assess efficacy and safety in many fields, such as biologics, cardiovascular, gene<br />
and cell therapy, immuniz<strong>at</strong>ion, musculoskeletal, neurology, nephrology, oncology,<br />
reproduction, development, nutrition.<br />
28
ANS BIOTECH - AUVERGNE<br />
NEUROSCIENCES<br />
Biopôle Clermont Limagne<br />
63360 SAINT BEAUzIRE - FRANCE<br />
Phone: +33 4 73 17 82 36<br />
Fax: +33 4 73 17 82 34<br />
Email: francois.caussade@ans-biotech.com<br />
Web site: www.ans-biotech.com<br />
Contact: François CAUSSADE<br />
ANS Biotech, a preclinical CRO dedic<strong>at</strong>ed to pain pharmacology, supports drug<br />
discovery and development efforts of companies involved in human and animal health,<br />
food and nutrition, by providing them with:<br />
• clinically relevant in vivo models for successful R&D of innov<strong>at</strong>ive analgesics,<br />
especially in the field of inflamm<strong>at</strong>ory pain, neurop<strong>at</strong>hic pain and visceral pain<br />
• customized scientific studies meeting drug discovery and development<br />
objectives<br />
• consulting activities.<br />
ARIANA<br />
PHARMACEUTICALS<br />
28 rue du Docteur Finlay<br />
75015 PARIS - FRANCE<br />
Phone: +33 01 44 37 17 00<br />
Fax: +33 01 44 37 17 01<br />
Email: info@arianapharma.com<br />
Web site: www.arianapharma.com<br />
Contact: Mohammad AFSHAR<br />
Ariana, a spin-off of the Institut Pasteur, is a leading decision support and d<strong>at</strong>a<br />
mining company, focused on transforming d<strong>at</strong>a into inform<strong>at</strong>ion to acceler<strong>at</strong>e the<br />
discovery and development of biomarkers and pharmaceutical drugs. Ariana has<br />
developed KEM ® (Knowledge Extraction Management), a proprietary decision support<br />
technology for rapid analysis of multi-parametric / multi-objective d<strong>at</strong>a. KEM is<br />
routinely applied to the identific<strong>at</strong>ion of Biomarkers, optimiz<strong>at</strong>ion in drug discovery,<br />
analysis of clinical d<strong>at</strong>a and early signal detection in drug safety.<br />
29
ATLANTIC BONE SCREEN<br />
1 rue Gaston Veil<br />
44035 NANTES Cedex 1 - FRANCE<br />
Phone: +33 2 40 41 11 25<br />
Fax: +33 2 40 41 28 35<br />
Email:<br />
morgane.bellus@<strong>at</strong>lantic-bone-screen.com<br />
Web site: www.<strong>at</strong>lantic-bone-screen.com<br />
Contact: Morgane BELLUS<br />
ATLANTIC BONE SCREEN is a french CRO focusing on bone and joint diseases and<br />
more particularly on bone diseases from tumor origin.<br />
Our company puts <strong>at</strong> its customers’ disposal a unique preclinical pl<strong>at</strong>form with a<br />
wide range of competitive in vitro and in vivo assays as well as histology and imaging<br />
services. This pl<strong>at</strong>form permits the detection, the evalu<strong>at</strong>ion and the scientific<br />
valid<strong>at</strong>ion of compounds presenting an interest <strong>at</strong> bone and joint level.<br />
AVOGADRO<br />
Parc de Génibr<strong>at</strong><br />
31470 FONTENILLES - FRANCE<br />
Phone: +33 5 62 14 73 14<br />
Fax: +33 5 62 14 73 10<br />
Email: avogadro@avogadro.fr<br />
Web site: www.avogadro-lab.com<br />
Contact: Marie-Christine BODINIER<br />
AVOGADRO / AMATSI: Toulouse - Montpellier, France & Cambridge, MA, USA.<br />
AVOGADRO / AMATSI (175 scientists) offers a wide range of services to its clients in<br />
the following fields:<br />
• pharmaceutical development (pre-formul<strong>at</strong>ion, formul<strong>at</strong>ion, analytical development,<br />
stability studies)<br />
• pre-clinical development (bioanalysis, PK, ADME, biochemistry, residues and TAS)<br />
• manufacturing, packaging, storage & distribution of clinical b<strong>at</strong>ches<br />
• quality control (raw m<strong>at</strong>erials and finished products).<br />
Our services are undertaken in a GLP and GMP assured environment (EMA, FDA)<br />
maintaining our core values (reactivity, flexibility and communic<strong>at</strong>ion).<br />
30
BIOFILM CONTROL<br />
Biopôle Clermont-Limagne<br />
63360 SAINT-BEAUzIRE - FRANCE<br />
Phone: +33 4 73 33 39 80<br />
Email: pascal.mayer@biofilmcontrol.com<br />
Web site: www.biofilmcontrol.com<br />
Contact: Pascal MAYER<br />
We leverage our unique and proprietary biological assays in order to be the first to<br />
discover compounds for fighting bacterial biofilms involved in triggering and sustaining<br />
severe and common human diseases.<br />
Our initial therapeutic targets are <strong>at</strong>opic derm<strong>at</strong>itis, acne, rhinosinusitis and pressure<br />
ulcers, each addressing a multi-billion Euro market.<br />
Our initial screening campaign with a focus on staphylococci has already identified<br />
a first set of active compounds with a promising chemical p<strong>at</strong>tern which we are now<br />
pushing into hit-to-lead and preclinical processes.<br />
BIO-MODELING SYSTEMS<br />
26 rue Saint Lambert<br />
75015 PARIS - FRANCE<br />
Phone: +33 6 83 06 12 72<br />
Email: manuel.gea@bmsystems.net<br />
Web site: www.bmsystems.net<br />
Contact: Manuel GEA<br />
BMSystems, is the first and to d<strong>at</strong>e the only systems biology company th<strong>at</strong> succeeded<br />
to cre<strong>at</strong>e in-silico heuristic models valid<strong>at</strong>ed in-vivo th<strong>at</strong> led to discoveries, p<strong>at</strong>ents,<br />
or oper<strong>at</strong>ional businesses through its innov<strong>at</strong>ive business model, in the fields of<br />
infectious diseases, neurology, psychi<strong>at</strong>ry, oncology and industrial biotech.<br />
Cre<strong>at</strong>ed in 2004, profitable since 2006, BMSystems is involved in the development its<br />
second spin-off in psychi<strong>at</strong>ric disorders after the success of its first one, Pherecydes-<br />
Pharma, in infectious diseases.<br />
31
BIOSIMS TECHNOLOGIES<br />
SEINE BIOPOLIS<br />
70 route de Lyons la forêt<br />
76000 ROUEN - FRANCE<br />
Phone: +33 2 76 08 60 24<br />
Fax: +33 2 35 52 93 33<br />
Email: christine.heuclin@biosims.fr<br />
Web site: www.biosims.fr<br />
Contact: Christine HEUCLIN<br />
BioSIMS has developed a unique Digital Protein Microarray Technology, which is a<br />
powerful research tool for low abundance targets in low volume samples. We are<br />
a specialized contract research organiz<strong>at</strong>ion, providing innov<strong>at</strong>ive solutions for<br />
detecting biomolecules and small chemical compounds, by using Secondary Ions<br />
Mass spectrometry (SIMS): the most sensitive of all the commonly used analytical<br />
techniques.<br />
The company’s objective is to develop new business opportunities in the biomarkers<br />
field with biotech and/ or pharmaceutical companies.<br />
BIOTRIAL<br />
7-9 rue Jean-Louis Bertrand<br />
35000 RENNES - FRANCE<br />
Phone: +33 2 99 59 91 91<br />
Fax: +33 2 99 59 91 97<br />
Email: damien.pillon@biotrial.co.uk<br />
Web site: www.biotrial.com<br />
Contact: Damien PILLON<br />
Founded in 1989, Biotrial is a leading full-service provider specialized in Early<br />
Development with a large range of services from Non-Clinical Pharmacology, Phase I<br />
studies, Phase II-IV Trial Management, Oncology, D<strong>at</strong>a Management, Biost<strong>at</strong>istics,<br />
ECG & Imaging Core Lab, Regul<strong>at</strong>ory Affairs to Medical Writing. Based in France<br />
(Paris & Rennes), the United Kingdom (London), and Belgium (Brussels), with an<br />
intern<strong>at</strong>ional team of 250 people, Biotrial performs hundreds of studies a year and<br />
offers tailor-made solutions to Pharma and Biotech companies. For 2011, Biotrial is<br />
pleased to announce a doubling of research capacity in Rennes, an increase in beds<br />
in the Paris Unit, a sales presence in Belgium and the disclosure of the site for the US<br />
Phase I Clinic.<br />
32
CABINET REGIMBEAU<br />
139 rue Vendôme<br />
69477 LYON Cedex 06 - FRANCE<br />
Phone: +33 4 72 83 85 70<br />
Fax: +33 4 78 24 30 78<br />
Email: tetaz@regimbeau.eu<br />
Web site: www.regimbeau.eu<br />
Contact: Franck TETAz<br />
Regimbeau Industrial Property Law Firm has supported public and priv<strong>at</strong>e sector<br />
companies and project owners for more than 80 years in protecting, strengthening<br />
and making profitable their innov<strong>at</strong>ions (p<strong>at</strong>ents, brand names, designs and models).<br />
10 partners head up a team of 200 people whose skills are put into practice in all the<br />
str<strong>at</strong>egic aspects of industrial property.<br />
Regimbeau’s expertise (Paris and its 5 regional offices in Lyon, Rennes, Grenoble,<br />
Montpellier and Munich) can provide an intern<strong>at</strong>ional str<strong>at</strong>egy, while maintaining a<br />
personalized rel<strong>at</strong>ionship of very high quality with its clients.<br />
CELLECTIS<br />
BIORESEARCH<br />
102 avenue Gaston Roussel<br />
93230 ROMAINVILLE - FRANCE<br />
Phone: +33 1 41 83 99 00<br />
Fax: +33 1 41 83 99 03<br />
Email: event@cellectis-bioresearch.com<br />
Web site: www.cellectis-bioresearch.com<br />
Contact: David LATTO<br />
Cellectis bioresearch specialize in cell line engineering for biotherapeutic production<br />
& development. Our technology can be used to modify the DNA sequence of<br />
customer cell lines with very high precision. We can engineer cell lines to contain a<br />
re-targetable gene expression cassette <strong>at</strong> a genomic protein production hot-spot in<br />
order to gre<strong>at</strong>ly reduce screening costs & time, gener<strong>at</strong>e stable & isogenic cell lines,<br />
achieve consistent protein expression levels & simplify regul<strong>at</strong>ion. We can also knockout<br />
genes to improve product quality, reduce purific<strong>at</strong>ion processes & increase cell<br />
half-life & productivity. For example, we are knocking-out the glutamine synthetase<br />
gene in Lonza’s CHOK1SV cell line to improve the selection process for cre<strong>at</strong>ing highly<br />
productive recombinant cell lines.<br />
33
CHELATEC<br />
1 rue Aronnax<br />
44821 SAINT-HERBLAIN Cedex - FRANCE<br />
Phone: +33 2 51 86 19 59<br />
Fax: +33 2 51 86 15 65<br />
Email: jfgestin@chel<strong>at</strong>ec.fr<br />
Web site: www.chel<strong>at</strong>ec.fr<br />
Contact: Jean-François GESTIN<br />
Chel<strong>at</strong>ec is an independent company providing customized service in the specific<br />
fields of radiolabeling and preclinical research.<br />
Our mission is to assist the pharmaceutical and biotechnology industry in the<br />
identific<strong>at</strong>ion and selection process of drug candid<strong>at</strong>es using the radioactive tracer.<br />
The broad expertise of our multidisciplinary team and the quality of our technical<br />
resources guarantee you optimum support for subcontracted projects. We offer a<br />
unique environment of labor<strong>at</strong>ories accredited in both the handling of radionuclides<br />
and animal experiment<strong>at</strong>ion conducted on rodents.<br />
CILOA<br />
cc107 - B<strong>at</strong>iment 24<br />
Universite Montpellier II - Place E. B<strong>at</strong>aillon<br />
34095 MONTPELLIER Cedex 05 - FRANCE<br />
Phone: +33 4 67 14 39 97<br />
Fax: +33 4 67 14 42 86<br />
Email: robert.mamoun@univ-montp2.fr<br />
Web site: www.ciloaweb.com<br />
Contact: Robert MAMOUN<br />
Ciloa is a start-up company with a proprietary technology th<strong>at</strong> provides fully n<strong>at</strong>ive<br />
membrane proteins on n<strong>at</strong>ural nanovesicles. Single and multi-transmembrane<br />
domain proteins sorted on these vesicles harbor all their n<strong>at</strong>ural post-transl<strong>at</strong>ional<br />
modific<strong>at</strong>ions. This revolutionary pl<strong>at</strong>form allows to produce custom membrane<br />
proteins out of cells for:<br />
1) drug screening<br />
2) innov<strong>at</strong>ive therapies<br />
3) gener<strong>at</strong>ion of new vaccines & monoclonal antibodies<br />
4) developing new kind of diagnostic tools.<br />
34
CLICDATA<br />
Place Francois Mitterrand<br />
1 Tour Crédit Lyonnais<br />
59777 EURALILLE - FRANCE<br />
Phone: +33 3 20 12 52 67<br />
Fax: +33 3 59 35 04 10<br />
Email: iain.wallace@clicd<strong>at</strong>a.com<br />
Web site: www.infinisworld.com<br />
Contact: Iain WALLACE<br />
ClicD<strong>at</strong>a presents Infinis, the Business Intelligence software next gener<strong>at</strong>ion, which<br />
builds a d<strong>at</strong>awarehouse autom<strong>at</strong>ically on the fly, allows you to cre<strong>at</strong>e amazing<br />
dashboards and reports in a few minutes. Oper<strong>at</strong>ional in less than 4 weeks, Infinis<br />
makes your Business Analysts and decision makers more productive and more<br />
confidents in the d<strong>at</strong>a. 2 priorities, rapidity (deployment and interface) and efficiency<br />
both for business and IT… all of it <strong>at</strong> a contained cost! Intrigued?<br />
www.infinisworld.com<br />
COLCOM<br />
Cap Alpha<br />
Avenue de l’Europe - Clapiers<br />
34940 MONTPELLIER Cedex 9 - FRANCE<br />
Phone: +33 6 24 34 42 94<br />
Fax: +33 4 67 63 10 46<br />
Email: info@colcom.eu<br />
Web site: www.colcom.eu<br />
Contact: Fabien GRANIER<br />
Nanotechnology based on “tree-like” polymers of Lysine with various possibilities of<br />
implement<strong>at</strong>ion for health, diagnostic, biom<strong>at</strong>erials and environmental applic<strong>at</strong>ions<br />
(production from g to kg). COLCOM has an exclusive know-how in chemistry and is<br />
mainly interested in collabor<strong>at</strong>ive research with industrial and academic partners.<br />
Fields of interest: antibodies production, biomarkers characteriz<strong>at</strong>ion, preclinical<br />
drug, transport of macromolecules across biological barriers, gene transfection, drug<br />
delivery, fluorescent molecule encapsul<strong>at</strong>ion, cell culture, biological traces detection,<br />
w<strong>at</strong>er filtr<strong>at</strong>ion, in vitro diagnostic.<br />
35
DBV TECHNOLOGIES<br />
Pépinière Paris Santé Cochin<br />
29 rue du Faubourg Saint Jacques<br />
75014 PARIS - FRANCE<br />
Phone: +33 1 55 42 78 78<br />
Fax: +33 1 43 26 10 83<br />
Email: phbenhamou@dbv-technologies.com<br />
Web site: www.dbv-technologies.com<br />
Contact: Pierre-Henri BENHAMOU<br />
dbv<br />
technologies<br />
DBV Technologies is the only company in the world whose products are designed<br />
to epicutaneously deliver an allergen - via a skin p<strong>at</strong>ch on intact skin - in order to<br />
diagnose and tre<strong>at</strong> food allergies. DBV’s proprietary skin p<strong>at</strong>ch technology - VIASKIN ® -<br />
is a breakthrough epicutaneous p<strong>at</strong>ch th<strong>at</strong> can desensitize against peanuts, milk<br />
and other major food allergies with dram<strong>at</strong>ic reduction in anaphylaxis risk. DBV is<br />
currently involved in 2 clinical trials for the Peanut Specific Immunotherapy: a Phase<br />
Ib in the US and a pilote Phase II in France…<br />
DOMAIN THERAPEUTICS<br />
Bioparc<br />
Boulevard Sébastien Brant<br />
67400 ILLKIRCH - FRANCE<br />
Phone: +33 3 90 40 61 50<br />
Fax: +33 3 90 40 61 55<br />
Email: contact@domaintherapeutics.com<br />
Web site: www.domaintherapeutics.com<br />
Contact: Pascal NEUVILLE<br />
Domain Therapeutics is a biopharmaceutical company loc<strong>at</strong>ed in Strasbourg, France,<br />
dedic<strong>at</strong>ed to the discovery and early development of small molecules targeting<br />
G-coupled Protein Receptors (GPCRs).<br />
Domain Therapeutics is using its innov<strong>at</strong>ive and proprietary technology pl<strong>at</strong>form<br />
DTect- All to address difficult GPCRs such as orphan and peptidic GPCRs for leading<br />
indic<strong>at</strong>ions such as Parkinson’s disease, schizophrenia, Alzheimer’s disease and<br />
diabetes.<br />
36
ERYTECH PHARMA<br />
60 avenue Rockefeller<br />
B<strong>at</strong>iment Adenine<br />
69008 LYON - FRANCE<br />
Phone: +33 4 78 74 44 38<br />
Fax: +33 4 78 78 93 00<br />
Email: contact@erytech.com<br />
Web site: www.erytech.com<br />
Contact: Pierre Olivier GOINEAU<br />
ERYtech Pharma (Lyon, Philadelphia) is a specialty pharma company developing<br />
innov<strong>at</strong>ive therapeutic solutions based on its proprietary technology and expertise<br />
in the physiological properties of erythrocytes. The company addresses serious<br />
p<strong>at</strong>hologies, orphan indic<strong>at</strong>ions or sub-popul<strong>at</strong>ions of p<strong>at</strong>ients, particularly in the<br />
fields of hem<strong>at</strong>ology, cancer and metabolic diseases.<br />
ERYtech Pharma US Office: 3711 Market Street, 19104 Philadelphia PA – USA.<br />
EUROFINS OPTIMED<br />
1 rue des Essarts<br />
38610 GIERES - FRANCE<br />
Phone: +33 4 38 37 27 40<br />
Fax: +33 4 38 37 27 41<br />
Email: marie.gilbert-collet@optimed.fr<br />
Web site: www.optimed.fr<br />
Contact: Marie GILBERT-COLLET<br />
<strong>French</strong> company founded in 1990, EUROFINS OPTIMED provides services for Early<br />
Drug Development (First into Human and First into P<strong>at</strong>ient studies, PK/PD studies,<br />
Proof of concept, etc.). EUROFINS OPTIMED has its own facilities on 2 sites with a<br />
full capacity of 100 beds including a hospital based unit. Thanks to its position within<br />
the Lyon Sud Hospital, Eurofins Optimed has access to various type of p<strong>at</strong>ients and a<br />
large network of experts. In addition to its services in pharmacology, Eurofins Optimed<br />
offers all services needed to achieve your study: regul<strong>at</strong>ory services, medical writing,<br />
monitoring, d<strong>at</strong>a management and st<strong>at</strong>istics.<br />
37
EVEON<br />
345 rue Lavoisier<br />
Inovallée<br />
38330 MONTBONNOT SAINT MARTIN<br />
FRANCE<br />
Phone: +33 4 76 44 84 17<br />
Email: mco@eveon.eu<br />
Web site: www.eveon.eu/en/index.html<br />
Contact: Muriel COMBEAU<br />
Eveon presents the first completely autom<strong>at</strong>ic and programmable medical injection<br />
device, fully safe, for SQ, ID and IM administr<strong>at</strong>ion of drugs of viscosities from 1 to<br />
100cp.<br />
The product is declined in a pl<strong>at</strong>form of devices th<strong>at</strong> could be mono-dose or multidoses,<br />
single-use or reusable.<br />
These devices also address other high-value applic<strong>at</strong>ions such as autom<strong>at</strong>ic LYO<br />
reconstitution or/and autom<strong>at</strong>ic mixing or/and dual injection.<br />
FLAMEL TECHNOLOGIES<br />
33 avenue du Dr Georges Levy<br />
69693 VENISSIEUX - FRANCE<br />
Phone: +33 4 7278 34 34<br />
Fax: +33 4 72 78 34 35<br />
Email: licencing@flamel.com<br />
Web site: www.flamel.com<br />
Contact: Grégoire FRANOUX<br />
FLAMEL Technologies (Nasdaq : FLML) is a world leader in delivery systems for small<br />
and large molecule drugs. The company, headquartered in Lyon, France, uses two<br />
innov<strong>at</strong>ive technology pl<strong>at</strong>forms, Micropumps ® and Medusa ® , to develop better and<br />
safer drugs tackling unmet medical needs.<br />
Flamel has 270 employees (70 PhDs) and ongoing RD collabor<strong>at</strong>ions and license<br />
agreements with many of the leading pharmaceutical and biotechnology companies<br />
(including GSK, Merck-Serono, Baxter and Pfizer).<br />
38
GELARC<br />
(Groupe d’ etude des L ymphomes de L’AduLte-r echer che cLinique/ AduLt<br />
Lymphom A study Group- cLinic AL r eseAr ch)<br />
Centre Hospitalier Lyon-Sud<br />
Secteur Sainte Eugénie - Pavillon 6D<br />
165 chemin du Grand Revoyet<br />
69495 PIERRE-BENITE Cedex - FRANCE<br />
Phone: +33 4 72 66 93 33<br />
Fax: +33 4 72 66 38 67<br />
Email: pascal.deschaseaux@gelarc.org<br />
Web site: www.gelarc.org<br />
Contact: Pascal DESCHASEAUX<br />
GELARC is a leading non-profit academic organiz<strong>at</strong>ion devoted to clinical research in<br />
the exclusive field of lymphoma. Founded in 2000, it is the daughter organiz<strong>at</strong>ion of the<br />
world renowned lymphoma cooper<strong>at</strong>ive group GELA (Groupe d’Etude des Lymphomes<br />
de l’Adulte/Adult Lymphoma Study Group). GELARC promotes and runs phase I to III<br />
clinical trials, for GELA, its academic partners and the pharma and biotech industries,<br />
<strong>at</strong> a n<strong>at</strong>ional or intern<strong>at</strong>ional level.<br />
GENOWAY<br />
181 avenue Jean Jaures<br />
Immeuble Ch<strong>at</strong>eaubriand<br />
69362 LYON - FRANCE<br />
Phone: +33 4 37 65 41 00<br />
Fax: +33 4 37 65 41 01<br />
Email: info@genoway.com<br />
Web site: www.genoway.com<br />
Contact: Dr. Kader THIAM<br />
genOway is dedic<strong>at</strong>ed to the development of tailor-made transgenic r<strong>at</strong> and mouse<br />
models for target valid<strong>at</strong>ion and drug development programs through innov<strong>at</strong>ive<br />
technologies (humaniz<strong>at</strong>ion, RNAi, inducible system) improving the security and<br />
relevancy of in vivo programs.<br />
Moreover, genOway offers ready-to-use transgenic r<strong>at</strong> and mouse models as tools<br />
to increase the predictability of in vivo preclinical studies in immunology, neurology,<br />
metabolic disorders and ADMET.<br />
39
GENTICEL<br />
Prologue Biotech - BP 28262<br />
Rue Pierre et Marie Curie<br />
31670 LABEGE - FRANCE<br />
Phone: +33 5 61 28 70 60<br />
Fax: +33 5 61 28 70 69<br />
Email: ebonfils@genticel.com<br />
Web site: www.genticel.com<br />
Contact: Elisabeth BONFILS<br />
GENTICEL S.A. is a bio-pharmaceutical company th<strong>at</strong> develops therapeutic vaccines<br />
based on a unique antigen delivery technology called the Adenyl<strong>at</strong>e Cyclase (CyaA).<br />
The str<strong>at</strong>egic goals of Genticel are (1) to ensure th<strong>at</strong> a vaccine solution can be offered<br />
to all HPV infected women in order to prevent cervical cancer and (2) to render<br />
available a further enhanced CyaA-based antigen delivery pl<strong>at</strong>form, called Vaxiclase,<br />
for applic<strong>at</strong>ions in cancer, chronic viral and bacterial infectious diseases. Genticel,<br />
named BT Pharma until March 9, 2010, was formed in 2001 as a spin out from the<br />
Institut Pasteur in Paris and is currently headquartered in Labége (Toulouse), France.<br />
The company employs 29 people.<br />
HARMONIC PHARMA<br />
Espace Transfert<br />
615 rue du Jardin Botanique<br />
54600 VILLERS LES NANCY - FRANCE<br />
Phone: +33 3 54 95 86 04<br />
Email: souchet@harmonicpharma.com<br />
gegout@harmonicpharma.com<br />
Web site: www.harmonicpharma.com<br />
HARMONIC PHARMA’s core business is directed towards repurposing clinical or<br />
approved drugs in new therapeutic areas. The company offers an innov<strong>at</strong>ive Harmonic<br />
Valid<strong>at</strong>ion © solution which exploits spherical harmonic based represent<strong>at</strong>ions of<br />
molecular entities for drug repositioning, and which currently draws on experimental<br />
in vitro/ex vivo valid<strong>at</strong>ions in four main therapeutic areas: Alzheimer disease, Infectious<br />
diseases, Diabetes rel<strong>at</strong>ed diseases, and Cancer.<br />
40
HELIOS BIOSCIENCES<br />
8 rue du Général Sarrail<br />
94010 CRÉTEIL Cedex - FRANCE<br />
Email: info@heliosbiosciences.com<br />
Web site: www.heliosbiosciences.com<br />
Contact:<br />
Dr. Jean Baptiste DUMAS MILNE EDWARDS<br />
In HELIOS BIOSCIENCES WE are convinced th<strong>at</strong> signalling p<strong>at</strong>hways are of<br />
outstanding importance to understand and cure diseases. Thus, we have developed<br />
an integr<strong>at</strong>ed system biology pl<strong>at</strong>form dedic<strong>at</strong>ed to the building of dynamic models of<br />
cell signalling. We use transcriptomic and/or proteomic and/or metabolic d<strong>at</strong>a. These<br />
dynamic models are used to select therapeutic targets and/or biomarkers. Our models<br />
can be used also to search for multi-targets.The technology th<strong>at</strong> we have designed<br />
has been used to develop models of immunostimul<strong>at</strong>ion of T lymphocytes, dendritic<br />
cells and also to build models of neurodegener<strong>at</strong>ive diseases. Using our models of<br />
immunostimul<strong>at</strong>ion we have selected and in vitro valid<strong>at</strong>ed Immunosuppressive drug<br />
targets which belong to a new p<strong>at</strong>hway.<br />
We offer an access to our dynamic modelling technology. Various option starting from<br />
the building of a dedic<strong>at</strong>ed model to the internalis<strong>at</strong>ion of the technology are proposed.<br />
We also look for partners to develop our new targets.<br />
HEMARINA<br />
Aéropôle Centre<br />
29600 MORLAIX - FRANCE<br />
Phone: +33 2 98 88 88 23<br />
Fax: +33 2 98 88 38 94<br />
Email: info@hemarina.com<br />
Web site: www.hemarina.com<br />
Contact: Jacques CHASSERIAU<br />
Hemarina is a biotechnology company developing a new gener<strong>at</strong>ion of universal<br />
oxygen carrier for therapeutical and industrial applic<strong>at</strong>ions.<br />
41
HTL BIOTECHNOLOGY<br />
zI de L’Aumaillerie<br />
35133 JAVENE - FRANCE<br />
Phone: +33 2 99 99 37 37<br />
Email: contact@htl-bio.com<br />
Web site: www.htl-bio.com<br />
Contact: Todd KENWORTH<br />
HTL s.a.s. was cre<strong>at</strong>ed in 1992 and is specialized in the manufacture, purific<strong>at</strong>ion<br />
and research and development of Sodium Hyaluron<strong>at</strong>e (HA). It’s production is by<br />
biosynthesis using a n<strong>at</strong>ural, non OGM, bacterial strain (Mw from 1000 Dalton to<br />
4 million Dalton. HTL’s production facility is cGMP, holds Certific<strong>at</strong>es of Suitability with<br />
the European Pharmacopoeia for low and high Mw Sodium Hyaluron<strong>at</strong>e, is ISO 9001<br />
(2000) and has a Master File (MAF) filed with the FDA (US),the TGA (Australia) and<br />
the Ministry of Health in South Korea.<br />
ICDD<br />
100 route des houillères - BP 2<br />
13590 MEYREUIL - FRANCE<br />
Phone: +33 4 42 61 28 28<br />
Fax: +33 4 42 61 28 29<br />
Email: ncompagnone@icdd-sas.com<br />
Web site: www.icdd-sas.com<br />
Contact: N<strong>at</strong>halie COMPAGNONE<br />
ICDD is a french biotech dedic<strong>at</strong>ed to diagnostic biomarkers development in safety<br />
and personal medicine. Our safety biomarkers are based on 2 technologies, Mitosafe ®<br />
and Mitostream ® , and we offer services, partnership or technology transfert to<br />
our customer or partner. Compagnon biomarkers are gener<strong>at</strong>ed through the<br />
Promembrane ® technology on 2 unmeet medical needs: early diagnosis of Alzheimer<br />
<strong>at</strong> the MCI stage, and muscles adverses events in AIDS p<strong>at</strong>ients.<br />
42
IMABIOTECH<br />
B<strong>at</strong>iment SN3 Cite Scientifique<br />
59655 VILLENEUVE D’ASCQ - FRANCE<br />
Phone: +33 6 32 94 03 51<br />
Fax: +33 3 20 43 40 54<br />
Email: stauber.jon<strong>at</strong>han@imabiotech.com<br />
Web site: www.imabiotech.com<br />
Contact: Jon<strong>at</strong>han STAUBER<br />
ImaBiotech offers services and products with an innov<strong>at</strong>ive technology of mass<br />
spectrometry imaging.<br />
ImaBiotech is a contract research organiz<strong>at</strong>ion (CRO) which provides Mass<br />
Spectrometry Imaging services for preclinical research (ADME and pharmacokinetics<br />
studies). With innov<strong>at</strong>ions and improvement of this technology, ImaBiotech also<br />
develops a new tool for immunodiagnostics.<br />
IMMUNID TECHNOLOGIES<br />
17 rue des Martyrs<br />
38054 GRENOBLE Cedex 09 - FRANCE<br />
Phone: +33 4 38 78 57 70<br />
Fax: +33 4 38 78 58 37<br />
Email: services@immunid.com<br />
Web site: www.immunid.com<br />
Contact: Isabelle TANNEAU<br />
ImmunID is a molecular diagnostics company th<strong>at</strong> uses the immune repertoire as a<br />
dynamic biomarker. Our team is dedic<strong>at</strong>ed to bringing solutions for the assessment<br />
of the efficacy and safety of immunomodul<strong>at</strong>ors during clinical trials and for p<strong>at</strong>ient<br />
str<strong>at</strong>ific<strong>at</strong>ion, in the areas of oncology and infectious diseases. ImmunID recently<br />
introduced the innov<strong>at</strong>ive concept of Divpenia ® (www.divpenia.com), a clinical st<strong>at</strong>e<br />
of reduced T & B lymphocytes immune diversity th<strong>at</strong> correl<strong>at</strong>es with a higher risk<br />
of infection and mortality. Divpenia ® can be used as a biomarker for early diagnosis,<br />
prognosis, response to tre<strong>at</strong>ment monitoring and p<strong>at</strong>ient str<strong>at</strong>ific<strong>at</strong>ion.<br />
43
IN-CELL-ART<br />
1 place Alexis Ricordeau<br />
44093 NANTES - FRANCE<br />
Phone: +33 2 40 71 67 17<br />
Email: info@incellart.com<br />
Web site: www.incellart.com<br />
IN CELL ART is a french biopharmaceutical company specializing in preclinical and<br />
pharmaceutical development of nanocarriers for macromolecular drugs. Its founder<br />
and research team, which includes a Nobel Prize Laure<strong>at</strong>e, have designed new classes<br />
of vectors th<strong>at</strong> are organized on a nanometric scale, which enables them to cross the<br />
cell barrier efficiently and safely. Products:<br />
• antibody production by genetic immuniz<strong>at</strong>ion. IN CELL ART technologies allows<br />
rapid and low cost production of antibodies with better specificity and affinity<br />
• DNA vaccine and siRNA therapeutics.<br />
INDICIA BIOTECHNOLOGY<br />
33 avenue de la Californie<br />
69600 OULLINS - FRANCE<br />
Phone: +33 4 72 39 14 92<br />
Fax: +33 4 72 39 16 01<br />
Email: infos@indicia.fr<br />
Web site: www.indicia.fr<br />
Contact: Stéphane LEGASTELOIS<br />
Indicia Biotechnology, specialist in immunotechnology and biochemistry, provides<br />
R&D and Manufacturing contracts to the biopharmaceutical and in vitro diagnostic<br />
industries to support their research, development of bioanalytical methods and<br />
safe production (under ISO 9001:2008, ISO13485, QSR and GMP intern<strong>at</strong>ional quality<br />
standards).<br />
We offer tailor-made solutions to measure biological targets (companion diag tests,<br />
methods to evalu<strong>at</strong>e immunogenicity, assays for biomarkers, immunomonitoring, QC<br />
methods…). Our technical services include immunoassays development and particles<br />
technologies (ELISA, Multiplex assays, l<strong>at</strong>eral flow, Singulex technology, a ntibodies<br />
development…).<br />
44
INGEN BIOSCIENCES<br />
17 avenue du Parc<br />
91380 CHILLY-MAzARIN - FRANCE<br />
Phone: +33 1 69 79 64 80<br />
Fax: +33 1 69 79 05 35<br />
Email: kadjoua@ingenbiosciences.com<br />
Web site: www.ingenbiosciences.com<br />
Contact: Kisy ADJOUA<br />
The InGen BioSciences Group is a <strong>French</strong> integr<strong>at</strong>ed IVD company th<strong>at</strong> develops and<br />
markets innov<strong>at</strong>ive diagnostic kits for clinical use, especially in the areas of infectious<br />
diseases and immunology.<br />
Leveraging its strong expertise in immunodiagnostics, the R&D develops IVD tests<br />
from research step to product industrializ<strong>at</strong>ion including regul<strong>at</strong>ory affairs. In parallel,<br />
the commercial organiz<strong>at</strong>ion pursues customer s<strong>at</strong>isfaction by offering high value<br />
reagents combined with autom<strong>at</strong>ion. Based in Paris area, the InGen BioSciences<br />
Group is growing profitably with sales reaching EUR 21M in 2010.<br />
INNOBIOCHIPS<br />
1 rue du Professeur Calmette<br />
59000 LILLE - FRANCE<br />
Phone: +33 3 20 87 12 98<br />
Email: contact@innobiochips.fr<br />
Web site: www.innobiochips.fr<br />
Contact: Vianney SOUPLET<br />
Innobiochips helps researchers leverage novel microanalytical technologies and<br />
acceler<strong>at</strong>e their discovery projects.<br />
With tailor-made solutions based on indepth knowledge of biomolecular chemistry<br />
and bioassays, Innobiochips helps the pharmaceutical, agrifood, cosmetics and<br />
environment industries provide new analytical tools and achieve superior performance<br />
levels (epitope mapping, multiplex serology, multi-proteins quantific<strong>at</strong>ion, biomarkers<br />
discovery…).<br />
45
INSTITUT MERIEUX<br />
17 rue Bourgel<strong>at</strong><br />
69002 LYON - FRANCE<br />
Phone: +33 4 78 87 72<br />
Email:<br />
philippe.cleuzi<strong>at</strong>@institut-merieux.com<br />
Web site: www.institut-merieux.com<br />
Contact: Philippe CLEUzIAT<br />
Institut Mérieux is committing its experience in industrial biology to serve medicine<br />
and public health across the globe. To fight against infectious diseases and cancers, it<br />
imagines and develops new approaches in the fields of diagnostics, immunotherapy,<br />
food safety and nutrition. Its three bio-industrial companies: bioMérieux, Transgene<br />
and Mérieux NutriSciences, working closely with its entities devoted to innov<strong>at</strong>ion,<br />
such as ABL Inc and Mérieux Développement, have enabled major advances in<br />
medicine and public health. Throughout the world, it aims to make these solutions<br />
accessible to the gre<strong>at</strong>est number of people.<br />
IRIS PHARMA<br />
Allée Hector Pintus<br />
06610 LA GAUDE - FRANCE<br />
Phone: +33 4 93 59 49 59<br />
Fax: +33 4 93 59 49 50<br />
Email: info@iris-pharma.com<br />
Web site: www.iris-pharma.com<br />
Contact: Pierre-Paul ELENA<br />
Iris Pharma is an independent <strong>French</strong> CRO th<strong>at</strong> specializes in preclinical and clinical<br />
research in the field of ophthalmology. Founded in 1989 by Dr Pierre-Paul Elena, Iris<br />
Pharma offers its services and expertise in the development of ophthalmic drugs and<br />
ocular medical devices to the pharmaceutical industry, biotechnology companies, and<br />
research institutes around the world.<br />
The company has five main areas of activity: preclinical studies and services,<br />
clinical trials (Phase I to IV and medico-marketing surveys), bioanalysis, preclinical<br />
formul<strong>at</strong>ion and str<strong>at</strong>egic consulting.<br />
46
KAYENTIS<br />
4 route de la Noue<br />
91190 GIF-SUR-YVETTE - FRANCE<br />
Phone: +33 1 69 18 25 40<br />
Fax: +33 1 64 46 79 06<br />
Email: agenovese@kayentis.com<br />
Web site: www.kayentis.com<br />
Contact: Anthony GENOVESE<br />
KAYENTIS is the leading vendor and oper<strong>at</strong>or of solutions th<strong>at</strong> transmit handwritten<br />
text from paper to digital media for the healthcare industry. Based on KAYENTIS’<br />
Digital Pen and Paper pl<strong>at</strong>form, these solutions bring together the best the physical<br />
and digital worlds have to offer: the easiest collection method (paper and pen) offering<br />
the highest d<strong>at</strong>a quality combined with all the advantages of electronic management<br />
(real-time access to d<strong>at</strong>a, accur<strong>at</strong>e timestamps, audit trail fe<strong>at</strong>ures, alerts, distribution<br />
of relevant inform<strong>at</strong>ion to the right persons).<br />
KAYENTIS’ solutions are used for over 50,000 p<strong>at</strong>ients in 50 countries.<br />
LABORATOIRE ICARE<br />
BIOPOLE Clermont-Limagne<br />
63360 SAINT-BEAUzIRE - FRANCE<br />
Phone: +33 4 73 33 99 99<br />
Fax: +33 4 73 33 99 77<br />
Email: commercial@labor<strong>at</strong>oireicare.com<br />
Web site: www.labor<strong>at</strong>oire-icare.com<br />
Contact: Christian POINSOT<br />
Pharmaceutical establishment, certified ISO 9001, accredited by the COFRAC<br />
and strictly respecting the GMP and the FDA requirements, ICARE is a labor<strong>at</strong>ory<br />
specialized in the control of contamin<strong>at</strong>ion.<br />
The strength of ICARE, which technical and human resources enable him to work <strong>at</strong><br />
the intern<strong>at</strong>ional level, lies in its capacity to upgrade its services in accordance with<br />
the regul<strong>at</strong>ions and norm<strong>at</strong>ive changes in pharmaceutical, medical devices, veterinary,<br />
cosmetics and clinics fields.<br />
47
LFB<br />
3 avenue des tropiques<br />
zA de Courtaboeuf<br />
91940 LES ULIS - FRANCE<br />
Phone: +33 1 68 82 88 69<br />
Fax: +33 1 69 82 70 70<br />
Email: soubiesg@lfb.fr<br />
Web site: www.lfb.fr<br />
Contact: Gail SOUBIES<br />
LFB Group is a biopharmaceutical group th<strong>at</strong> develops, manufactures and markets<br />
medicinal products for the tre<strong>at</strong>ment of serious and often rare diseases in several<br />
major therapeutic areas: immunology, intensive care and hemostasis. LFB Group<br />
is the leading manufacturer of plasma-derived medicinal products in France and<br />
the 6th player worldwide. It is also among the leading European companies for<br />
the development of monoclonal antibodies and new-gener<strong>at</strong>ion proteins based on<br />
biotechnologies. In 2010, LFB’s turnover reached €411.6 million; €86.5 million were<br />
dedic<strong>at</strong>ed to the group’s R&D activities. Christian Béchon is president and CEO of the<br />
LFB Group (1835 employees). For more inform<strong>at</strong>ion about LFB: http://www.lfb.fr/<br />
MAGNISENSE<br />
27 chemin des Peupliers - BP 62<br />
69572 DARDILLY Cedex - FRANCE<br />
Phone: +33 1 45 62 82 64<br />
Email: info@magnisense.com<br />
Web site: www.magnisense.com<br />
Contact: Hay<strong>at</strong> EL YOUSFI<br />
Magnisense develops and markets magnetic bioassays. These next-gener<strong>at</strong>ion assays<br />
improve rapid diagnostic performance for human and animal diagnostics, food safety<br />
and environmental protection testing. They are based on magnetic bead markers,<br />
which can be used to achieve the accuracy of labor<strong>at</strong>ory testing with the ease of use<br />
of rapid test methods. Magnisense technology provides true quantific<strong>at</strong>ion of one or<br />
more biological targets, even in large volume samples. The magnetic signal is free of<br />
interference from environmental factors, permitting a more sensitive and reproducible<br />
detection than possible with traditional markers.<br />
48
MEDINCELL<br />
Cap Alpha<br />
Avenue de l’Europe<br />
34830 MONTPELLIER Cedex 9 - FRANCE<br />
Phone: +33 9 50 51 81 61<br />
Fax: +33 4 67 02 13 67<br />
Email: sebastien.enault@medincell.com<br />
Web site: www.medincell.com<br />
Contact: Sébastien ENAULT<br />
Medincell S.A. is a leading biopharmaceutical company loc<strong>at</strong>ed in France and USA<br />
th<strong>at</strong> offers an innov<strong>at</strong>ive Drug Delivery Pl<strong>at</strong>form, enhancing the delivery of active<br />
agents, improving p<strong>at</strong>ient compliance and convenience thanks to advantageous<br />
pharmacokinetic profiles.<br />
MEDIT<br />
2 rue du Belvédère<br />
91120 PALAISEAU - FRANCE<br />
Phone: +33 1 60 14 87 43<br />
or +1 (858)342 6807 (San Diego office)<br />
Fax: +33 1 83 63 67 46<br />
Email: fdelfaud@medit.fr<br />
srichard@medit.fr<br />
Web site: www.medit.fr<br />
MEDIT-SA develops innov<strong>at</strong>ive software to mine <strong>at</strong> Chemo-Proteomic level all<br />
Biostructural and SAR d<strong>at</strong>a. Applic<strong>at</strong>ions include: 1) Allosteric site detection •<br />
2) Functional annot<strong>at</strong>ion • 3) Binding site characteriz<strong>at</strong>ion • 4) Target druggability •<br />
5) Off target identific<strong>at</strong>ion • 6) Drug repurposing • 7) Scaffold hopping • 8) Bioisosterism<br />
replacement • 9) Fragment binding prediction • 10) Fragment-based drug design •<br />
11) Protein-protein interactions. In April 2011, we release MEDL-Bioisostere to provide<br />
bioisosteric replacement from protein-fragment local 3D similarities detected into the<br />
Protein D<strong>at</strong>a Bank, and MEDP-SiteClassifier to explore all binding site similarities <strong>at</strong><br />
PDB scale.<br />
49
METABRAIN RESEARCH<br />
4 avenue François Mitterrand<br />
91380 CHILLY-MAzARIN - FRANCE<br />
Phone: +33 1 69 19 41 50<br />
Fax: +33 1 69 19 41 51<br />
Email: contact@metabrainresearch.com<br />
Web site: www.metabrainresearch.com<br />
Contact: Valérie AUTIER<br />
Metabrain Research is a drug discovery Partnering Research Organis<strong>at</strong>ion (PRO)<br />
expert in metabolic disorders.<br />
Metabrain Research has a sustainable business model of early stage drug discovery<br />
research, based on a mix of research alliances, early stage collabor<strong>at</strong>ions and contract<br />
research. Our objectives <strong>at</strong> BIO :<br />
1) propose research alliances on first-in-class programs<br />
2) contribute to drug discovery programs through contract research<br />
3) initi<strong>at</strong>e collabor<strong>at</strong>ions building on the connections between metabolic and CNS<br />
disorders to valid<strong>at</strong>e novel targets and discover new drugs.<br />
MILLEGEN<br />
Immeuble Biostep - B<strong>at</strong>. A<br />
Rue Pierre et Marie Curie<br />
31681 LABEGE - FRANCE<br />
Phone: +33 5 61 28 70 10<br />
Fax: +33 5 61 28 70 11<br />
Email: contact@millegen.com<br />
Web site: www.millegen.com<br />
Contacts: Anne DEFLISQUE<br />
Philippe MONDON<br />
Millegen is expert in discovery and genetic engineering of therapeutic antibodies.<br />
MilleGen’s antibody pl<strong>at</strong>form allows the gener<strong>at</strong>ion of fully human monoclonal<br />
antibodies and lead optimiz<strong>at</strong>ion using a powerful Directed Molecular Evolution<br />
technology. Our specificity is to have a proprietary library comprising several billion<br />
different fully human antibodies with an original diversity. Our efficiency was proven<br />
through several successful projects with industrial partners. MilleGen has built<br />
a pipeline of therapeutic antibodies. We are looking to associ<strong>at</strong>e human antibody<br />
candid<strong>at</strong>es to original targets to develop with you a targeted therapy.<br />
50
NETRIS PHARMA<br />
Centre Léon Bérard<br />
28 rue Laennec<br />
69008 LYON - FRANCE<br />
Phone: +33 4 78 78 29 53<br />
Fax: +33 4 78 78 28 04<br />
Email: pascalenony@netrispharma.com<br />
Web site: www.netrispharma.com<br />
Contact: Pascale NONY<br />
NETRIS Pharma is a biotech company pioneer in the characteriz<strong>at</strong>ion and development<br />
of drug candid<strong>at</strong>es targeting the Dependence Receptors p<strong>at</strong>hway for cancer therapy.<br />
The therapeutic approach is based on cellular mechanisms identified by a worldrenowned<br />
research group and has not yet been explored by pharmaceutical companies.<br />
NETRIS Pharma evalu<strong>at</strong>es and develops drug candid<strong>at</strong>es until the end of preclinical<br />
or phase I and proposes licensing and collabor<strong>at</strong>ive agreements. NETRIS Pharma has<br />
several high-value candid<strong>at</strong>es in its pipeline for therapy of lung and breast cancers as<br />
well as neuroblastoma among others.<br />
NEUROFIT<br />
Boulevard Sébastien Brant<br />
Bioparc - Parc d’Innov<strong>at</strong>ion<br />
67400 ILLKIRCH - FRANCE<br />
Phone: +33 3 88 65 16 06<br />
Fax: +33 3 88 65 16 22<br />
Email: neurofit@neurofit.com<br />
Web site: www.neurofit.com<br />
Contact: Dr. Emile ANDRIAMBELOSON<br />
NEUROFIT is a pre-clinical CRO (Contract Research Organiz<strong>at</strong>ion) based in France<br />
and offering comprehensive list of disease models and screening assays in the fields<br />
of psychi<strong>at</strong>ry, neurology, multiple sclerosis, diabetes, pain and oncology. Neurofit’s<br />
expertise encompasses animal (in-vivo) experiment<strong>at</strong>ions and primary cell culture<br />
assays. Neurofit works for major pharmaceutical and Biotech companies in Europe<br />
and USA.<br />
51
NICOX<br />
1681 route des Dolines<br />
Les Taissounières - HB4 - BP 313<br />
06906 SOPHIA ANTIPOLIS - FRANCE<br />
Phone: +33 4 97 24 53 00<br />
Fax: +33 4 97 24 53 99<br />
Email: nicox@nicox.com<br />
Web site: www.nicox.com<br />
Contact: Gavin SPENCER<br />
NicOx is a pharmaceutical company focused on the research, development and<br />
future commercializ<strong>at</strong>ion of drug candid<strong>at</strong>es. NicOx is applying its proprietary nitric<br />
oxide-don<strong>at</strong>ing R&D pl<strong>at</strong>form to develop an internal portfolio of New Molecular<br />
Entities (NMEs) for the potential tre<strong>at</strong>ment of inflamm<strong>at</strong>ory, cardio-metabolic and<br />
ophthalmological diseases.<br />
NicOx’s lead investig<strong>at</strong>ional compound is naproxcinod, an NME in development for the<br />
relief of the signs and symptoms of osteoarthritis. In addition to naproxcinod, NicOx’s<br />
pipeline includes several nitric oxide-don<strong>at</strong>ing NMEs, which are in development<br />
internally and with partners, including Merck (known as MSD outside the United<br />
St<strong>at</strong>es and Canada) and Bausch + Lomb, for the tre<strong>at</strong>ment of select cardiovascular<br />
indic<strong>at</strong>ions, eye diseases and derm<strong>at</strong>ological diseases.<br />
NOKAD<br />
4 rue Pierre Fontaine<br />
91000 EVRY - FRANCE<br />
Phone: +33 1 60 87 89 86<br />
Fax: +33 1 60 87 89 99<br />
Email: contact@nokad-pharma.com<br />
Web site: www.nokad.fr<br />
Contact: Amine M. ABINA<br />
NOKAD has developed a target valid<strong>at</strong>ion pl<strong>at</strong>form using both in vivo and ex vivo<br />
models allowing the discovery of new p<strong>at</strong>hways in hem<strong>at</strong>ology and cancer with the<br />
aim to develop new therapeutic str<strong>at</strong>egies and biomarkers. NOKAD is developing a<br />
biomarker blood test to str<strong>at</strong>ify an individual risk of developing thrombosis following<br />
Erythropoietin tre<strong>at</strong>ment and in hypoxia-stressed p<strong>at</strong>ients. Other projects under<br />
development include therapeutic vaccin<strong>at</strong>ion in cancer and development of new<br />
vaccine str<strong>at</strong>egies in infectious diseases.<br />
52
NOSOPHARM<br />
Site EERIE - Parc Georges Besse<br />
30035 NIMES Cedex 01 - FRANCE<br />
Phone: +33 9 65 15 10 93<br />
Fax: +33 4 86 55 63 42<br />
Email: p.villainguillot@nosopharm.com<br />
Web site: www.nosopharm.com<br />
Contact: Philippe VILLAIN-GUILLOT<br />
Nosopharm discovers and develops novel first-in-class antibiotics by the medicinal<br />
mining of a novel microbial bioresource. Nosopharm aims to out-license its novel<br />
antibiotics <strong>at</strong> the preclinical stage.<br />
NOVALIX<br />
Bioparc<br />
Boulevard Sébastien Brant<br />
67400 ILLKIRCH - FRANCE<br />
Phone: +33 3 68 33 02 00<br />
Fax: +33 3 68 33 02 01<br />
Email: info@novalix-pharma.com<br />
Web site: www.novalix.com<br />
Contact: Denis zEYER<br />
NovAliX is focusing on the development of enabling chemistry and biophysical<br />
technologies to support the pharmaceutical industry’s outsourcing needs from<br />
discovery to manufacturing. With proprietary unique SPR technology, X-ray protein<br />
crystallography, supramolecular mass spectrometry and chemistry NovAliX offers<br />
comprehensive integr<strong>at</strong>ed services for small molecule drug discovery. With advanced<br />
NMR technologies, NovAliX provides fine characteriz<strong>at</strong>ion of biologics, thorough<br />
analysis of APIs and polymorphism studies to support pharmaceutical development<br />
and manufacturing teams.<br />
53
ONCODESIGN<br />
20 rue Jean Mazen - BP 27627<br />
21076 DIJON - FRANCE<br />
Phone: +33 3 80 78 82 60<br />
Fax: +33 3 80 78 82 61<br />
Email: spomeon@oncodesign.com<br />
jewing@oncodesign.com<br />
Web site: www.oncodesign.com<br />
Contact: Jon<strong>at</strong>han EWING<br />
The recent acquisition of the Nanocyclix technology pl<strong>at</strong>form is a perfect complement<br />
to Oncodesign’s recognized expertise and capabilities in transl<strong>at</strong>ional oncology<br />
research. Oncodesign’s capabilities now extend to therapeutic drug and diagnostic<br />
discovery offerings through an integr<strong>at</strong>ed, stand-alone approach. Chi-Mice ® pl<strong>at</strong>form:<br />
humanized mouse models consisting of low passage, p<strong>at</strong>ient-derived tumorgrafts<br />
as well as mice reconstituted with human immune system. PharmImage ® : a multimodality<br />
pharmaco-imaging pl<strong>at</strong>form for rodents equipped with MRI, MRS, PET and<br />
SPECT. Conventional pharmacology studies in mice and r<strong>at</strong>s.<br />
ONCOMEDICS<br />
1 avenue d’Ester<br />
87069 LIMOGES - FRANCE<br />
Phone: +33 5 55 33 85 25<br />
Fax: +33 5 55 33 85 26<br />
Email: contact@oncomedics.com<br />
Web site: www.oncomedics.com<br />
Contact: Christophe LAUTRETTE<br />
Oncomedics collect human cancer tumor from p<strong>at</strong>ients to obtain cancer primary<br />
culture as models for cancer research: drug screening, biomarker valid<strong>at</strong>ion… Our<br />
models are defined and valid<strong>at</strong>ed to evalu<strong>at</strong>e experimental drug efficiency on a panel<br />
of tumoral cell from distinct p<strong>at</strong>ient. Moreover, specific marker can be searched<br />
on our ex vivo models. Correl<strong>at</strong>ion between new drug candid<strong>at</strong>e and companion<br />
biomarker can be addressed too. We sell chemically defined medium for tumor cells<br />
conserv<strong>at</strong>ion, prepar<strong>at</strong>ion, and primary culture.<br />
54
ONLY FOR CHILDREN<br />
PHARMACEUTICALS<br />
Institut Villemin<br />
10 avenue de Verdun<br />
75010 PARIS - FRANCE<br />
Phone: +33 1 57 27 86 87<br />
or +33 6 98 71 02 12<br />
Fax: +33 1 57 27 86 80<br />
Email: estelle.habert-ortoli@o4cp.com<br />
Web site: www.o4cp.com<br />
Contact: Estelle HABERT-ORTOLI<br />
Only for children pharmaceuticals ® (O4CP) is a <strong>French</strong> pharmaceutical company (SAS)<br />
founded in 2007 developing adapted medicines for children. The company addresses<br />
an important unmet medical need th<strong>at</strong> experts and regul<strong>at</strong>ory authorities have clearly<br />
identified: the need for adapted medicines for children. O4CP is active in Oncology,<br />
Immunology, Infectious Diseases and Neurology, and present in Europe (Paris, France)<br />
and United St<strong>at</strong>es. O4CP is developing a pipeline of 8 molecules.<br />
OROXCELL<br />
102 avenue Gaston Roussel<br />
Parc Biocitech<br />
93230 ROMAINVILLE - FRANCE<br />
Phone: +33 1 41 83 72 20<br />
Fax: +33 1 41 83 72 27<br />
Email: christophe.dini@oroxcell.com<br />
Web site: www.oroxcell.com<br />
Contact: Christophe DINI<br />
Oroxcell is pursuing drug research and development of NCEs in the indic<strong>at</strong>ion of Pain.<br />
Oroxcell is seeking a partner wishing to undertake the development and marketing of<br />
the safe and active NCEs.<br />
Besides, Oroxcell is a well-recognized CRO offering a unique one-stop-shopping<br />
pl<strong>at</strong>form to assess skin and oral absorption (ADME) and Toxicity profile form issued<br />
life sciences industry. Oroxcell is actively involved in setting up unique predictive<br />
altern<strong>at</strong>ive technologies to animal. Oroxcell is GLP compliant for both cosmetic and<br />
pharmaceutical activities.<br />
55
PHARMAXON<br />
Parc Scientifique de Luminy - Case 922<br />
Grand Luminy Technopôle<br />
13288 MARSEILLE Cedex 9 - FRANCE<br />
Phone: +33 4 86 94 85 10<br />
Fax: +33 4 86 94 85 11<br />
Email: norreel@pharmaxon.com<br />
Web site: www.pharmaxon.com<br />
Contact: Jean-Chrétien NORREEL<br />
Founded in 2004, Pharmaxon is a mid-stage venture biopharmaceutical company<br />
developing first-in-class neurological disease therapeutics. Pharmaxon’s novel<br />
approach is linked to the pharmacological manipul<strong>at</strong>ion of “cell mobility”, a process<br />
central to many high unmet medical need neurological conditions. The goal of<br />
Pharmaxon’s in 2010 is to complete the preclinical toxicity studies for its lead molecule<br />
PR-21 (a spinal cord injury therapeutic with a wide range of additional high-value<br />
indic<strong>at</strong>ions).<br />
OXELTIS<br />
Cap Gamma<br />
1682 rue de la Valsière - CS 27384<br />
34189 MONTPELLIER Cedex 4 - FRANCE<br />
Phone: +33 4 99 23 50 36<br />
Fax: +33 9 70 06 43 82<br />
Email: contact@oxeltis.com<br />
Web site: www.oxeltis.com<br />
Contact: Jean-Marc ALLAIRE<br />
Oxeltis is a medicinal chemistry oriented service company for managing and executing<br />
projects involving medicinal and fine organic chemistry in the fields of pharmaceutical,<br />
diagnostic and academic research. Oxeltis has expertise in the fields of organic<br />
chemistry represented by nucleosides and nucleotides, heterocycles, macrocycles,<br />
Phosphorus and Flurorine Chemistry. Since February 2011, Oxeltis has put in place<br />
a routine nucleoside triphosph<strong>at</strong>e custom synthesis capability and has focused<br />
its knowhow in fields of applic<strong>at</strong>ion of medicinal chemistry in pharmaceutical drug<br />
discovery, and also in the field of diagnostic and research tools.<br />
56
PHENOPRO<br />
1 rue Laurent Fries<br />
67400 ILLKIRCH - FRANCE<br />
Phone: +33 3 88 65 57 36<br />
Fax: +33 3 88 65 56 07<br />
Email: francois.bocquel@phenopro.com<br />
Contact: François Bocquel<br />
PhenoPro is a spin off from IGBMC and the <strong>French</strong> Mouse Clinical Institute loc<strong>at</strong>ed in<br />
Strasbourg (France).<br />
PhenoPro is a pre-clinical Contract Research Organiz<strong>at</strong>ion dedic<strong>at</strong>ed to comprehensive<br />
mouse model phenotyping services with expertise in Cardiovascular, Metabolism and<br />
CNS & Behavior domains.<br />
The innov<strong>at</strong>ive approach of phenotyping with genetically-modified mice allows:<br />
• the process of discovering new drugs to be acceler<strong>at</strong>ed<br />
• shifts and delays to be avoided <strong>at</strong> l<strong>at</strong>er stages in the development plan<br />
• research costs to be optimised.<br />
POLYPLUS-<br />
TRANSFECTION<br />
Bioparc<br />
Boulevard Sebastien Brant<br />
67401 ILLKIRCH - FRANCE<br />
Phone: +33 3 90 40 61 80<br />
Fax: +33 3 90 40 61 81<br />
Email: info@polyplus-transfection.com<br />
Web site: www.polyplus-transfection.com<br />
Contact: Pascale BELGUISE<br />
Polyplus-transfection is a biotechnology company th<strong>at</strong> develops, markets and sells<br />
innov<strong>at</strong>ive solutions for in vivo, in vitro and ex vivo delivery of nucleic acids in research,<br />
bioproduction and therapeutics. Polyplus-transfection supplies its proprietary range<br />
of reagents for the transfection of genes, oligonucleotides and siRNA in vitro and in<br />
vivo through a worldwide distributor network. Polyplus-transfection reagents are<br />
involved into a growing number of clinical trials worldwide.<br />
57
PORSOLT<br />
9 bis rue Henri Martin<br />
92100 BOULOGNE-BILLANCOURT<br />
FRANCE<br />
Phone: +33 1 46 10 99 90<br />
Fax: +33 1 46 10 99 99<br />
Email: twolinsky@porsolt.com<br />
Web site: www.porsolt.com<br />
Contact: Dr. Toni WOLINSKY<br />
Priv<strong>at</strong>ely owned CRO, with over 25 years of experience, specialized in the preclinical<br />
evalu<strong>at</strong>ion of novel substances for their potential therapeutic activity (efficacy<br />
pharmacology) and adverse effects (safety pharmacology, including regul<strong>at</strong>ory<br />
GLP studies). We provide a wide range of in vivo p<strong>at</strong>hophysiological models and in<br />
vitro assays across a variety of disease areas covering CNS, pain & inflamm<strong>at</strong>ion,<br />
metabolic and cardiovascular diseases, and gastro-intestinal, renal/urogenital &<br />
respir<strong>at</strong>ory indic<strong>at</strong>ions, as well as evalu<strong>at</strong>ion of cardiovascular risk and drug abuse<br />
and dependence liability. We also offer in-life PK studies, including CSF sampling, in<br />
a number of species.<br />
POXEL<br />
200 avenue Jean Jaurès<br />
69007 LYON - FRANCE<br />
Phone: +33 4 37 37 20 10<br />
Fax: +33 4 37 70 88 15<br />
Email: contact@poxelpharma.com<br />
Web site: www.poxel.com<br />
Contact: Pascale MALGOUYRES<br />
Poxel is a biopharmaceutical company developing innov<strong>at</strong>ive first-in-class drugs<br />
with a primary focus on Type 2 diabetes. The company develops drug candid<strong>at</strong>es to<br />
clinical proof of concept before partnering with pharmaceutical companies. Poxel<br />
oper<strong>at</strong>es independently as a lean organiz<strong>at</strong>ion with strong in-house drug development<br />
expertise. Its pipeline consists in innov<strong>at</strong>ive projects with new mechanisms of action,<br />
with an activity on glucose metabolism, other cardiovascular risk factors and with an<br />
improved safety profile compared to currently available therapies.<br />
58
PRESTWICK CHEMICAL<br />
Boulevard Gonthier d’Andernach<br />
67400 STRASBOURG-Illkirch - FRANCE<br />
Phone: +33 3 69 20 16 00<br />
Fax: +33 3 69 20 16 17<br />
Email: infochem@prestwickchemical.fr<br />
Web site: www.prestwickchemical.com<br />
Contact: Paul BIKARD<br />
Prestwick Chemical is a drug discovery CRO th<strong>at</strong> successfully optimizes your hit<br />
into a clinical candid<strong>at</strong>e. With our premium partners, we offer fully integr<strong>at</strong>ed drug<br />
research: Hit identific<strong>at</strong>ion using smart screening libraries, hit valid<strong>at</strong>ion, hit to lead<br />
expansion, lead optimiz<strong>at</strong>ion and profiling. Our in-house expertise relies on long<br />
term experience in medicinal chemistry, with unprecedented success: 6 compounds<br />
made by Prestwick are currently in clinical development, from Phase I to Phase III. In<br />
l<strong>at</strong>e 2010, one project (developed jointly with Domain Therapeutics) was successfully<br />
licensed to Merck Serono.<br />
PROVEPHARM<br />
45 rue Frédéric Joliot Curie<br />
BP 100 - Technopôle Château Gombert<br />
13013 Marseille - FRANCE<br />
Phone: +33 4 91 11 87 59<br />
Fax: +33 4 91 11 88 11<br />
Email:<br />
christian.neumann@provepharm.com<br />
Web site: www.provepharm.com<br />
Contact: Christian NEUMANN<br />
Thanks to a p<strong>at</strong>ented synthesis p<strong>at</strong>h and genuine scientific work, PROVEPHARM<br />
revamped methylene blue compound as PROVEBLUETM Active Pharmaceutical<br />
Ingredient compliant with all pharmaceutical standards and ICH guidelines, developed<br />
the drug Proveblue Solution for Injection and obtained a centralized marketing<br />
authoriz<strong>at</strong>ion <strong>at</strong> EMA. It is now seeking to introduce the drug in US and to license-out<br />
the use of ProveblueTM API to parties interested in setting up exclusive partnerships<br />
to develop other drugs in well-defined applic<strong>at</strong>ions.<br />
59
PX’THERAPEUTICS<br />
Min<strong>at</strong>ec BHT 52B<br />
7 parvis Louis Néel<br />
38040 GRENOBLE - FRANCE<br />
Phone: +33 4 38 02 36 50<br />
Fax: +33 4 76 96 10 38<br />
Email: marketing@px-therapeutics.com<br />
Web site: www.px-therapeutics.com<br />
Contact: Claire UNTEREINER<br />
PX’Therapeutics provides services in the field of recombinant protein and monoclonal<br />
antibody development, from early research stage up to clinical manufacturing.<br />
We propose custom programs including, according to our clients’ needs, protein<br />
engineering, murine mAb development, mAb humaniz<strong>at</strong>ion, feasibility studies,<br />
process development, analytical method development & qualific<strong>at</strong>ion, process scaleup<br />
and GMP manufacturing.<br />
Through our subsidiary Promise Advanced Proteomics, we propose an innov<strong>at</strong>ive<br />
method of protein quantific<strong>at</strong>ion by Mass spectrometry.<br />
QUINTEN<br />
11 rue Galvani<br />
75017 PARIS - FRANCE<br />
Phone: +33 6 08 43 82 81<br />
Email: a.templier@quinten-france.com<br />
Web site: www.quinten-healthcare.com<br />
Contact: Alexandre TEMPLIER<br />
Quinten ® is specialized in Knowledge Extraction from Medical D<strong>at</strong>abases. Quinten’s<br />
core professional service consists in helping Pharma & Biotech companies identify the<br />
specific conditions in which their drugs show the best efficacy and safety performances,<br />
to better target their Research & Development programs and improve their success<br />
r<strong>at</strong>es. Quinten ® methodology and technology have proven to gener<strong>at</strong>e significant<br />
return on investment for its clients in various contexts such as early chemical lead<br />
optimiz<strong>at</strong>ion, Phase III study design optimiz<strong>at</strong>ion, and epidemiology / safety d<strong>at</strong>abases<br />
explor<strong>at</strong>ion.<br />
60
RHENOVIA PHARMA<br />
20C rue de Chemnitz<br />
68200 MULHOUSE - FRANCE<br />
Phone: +33 3 89 32 11 80<br />
Fax: +33 3 89 55 51 45<br />
Email: serge.bischoff@rhenovia.com<br />
Web site: www.rhenovia.com<br />
Contact: Serge BISCHOFF<br />
Rhenovia is a leading biotech company in biosimul<strong>at</strong>ion with a unique service offering<br />
for biopharma companies to acceler<strong>at</strong>e, reduce the costs and improve the success<br />
r<strong>at</strong>e of their Drug Development for neurodegener<strong>at</strong>ive and psychi<strong>at</strong>ric diseases. It<br />
uses breakthrough technology of modeling the cellular and molecular cascades of<br />
neuronal transmission and simul<strong>at</strong>ing functional biochemical and electrophysiological<br />
measures for in silico testing of drug effects under p<strong>at</strong>hological conditions. It further<br />
develops a high-tech r<strong>at</strong>e controlled p<strong>at</strong>ch for drugs and combin<strong>at</strong>ions optimized by<br />
simul<strong>at</strong>ion.<br />
ROOWIN<br />
102 avenue Gaston Roussel<br />
93230 ROMAINVILLE - FRANCE<br />
Phone: +33 6 61 95 34 50<br />
Fax: +33 1 41 83 71 94<br />
Email: p<strong>at</strong>rice.rool@roowin.fr<br />
Web site: www.roowin.com<br />
Contact: Dr. P<strong>at</strong>rice ROOL<br />
Roowin is a Contract Research/Manufacturing Organiz<strong>at</strong>ion (CRO/CMO) offering a one<br />
stop shopping services from early discovery research phase up to licensing out API in<br />
Phase II. These services include: hit to lead, lead optimiz<strong>at</strong>ion, process development,<br />
custom synthesis, cGMP production of API, analysis services, analytical method<br />
development, analytical method valid<strong>at</strong>ion, stability studies.<br />
Roowin’s team is formed with highly qualified scientific chemists: about 40 people<br />
(50% PhDs) working in 2000 m 2 of R&D labor<strong>at</strong>ories, kilo-labor<strong>at</strong>ory and pilot plant,<br />
equipped with adapted and efficient equipments.<br />
61
SYNTHELIS<br />
B<strong>at</strong>iment Biopolis<br />
5 avenue du Grand Sablon<br />
38700 LA TRONCHE - FRANCE<br />
Phone: +33 4 76 54 95 37<br />
Fax: +33 4 76 54 95 36<br />
Email: bruno.tillier@synthelis.fr<br />
Web site: www.synthelis.fr<br />
Contact: Bruno TILLIER<br />
Synthelis SAS is a start-up company providing a solution to a well known challenge<br />
in terms of biotechnological production, namely the development, characteriz<strong>at</strong>ion<br />
and production of customized membrane proteins and associ<strong>at</strong>ed service offerings.<br />
The company is also working on its own R&D programs with a view to developing<br />
innov<strong>at</strong>ive therapeutic and vaccine approaches based on membrane protein carried<br />
into liposomes<br />
TB DRUG BOOST<br />
3 rue du Professeur Laguesse<br />
59000 LILLE - FRANCE<br />
Phone: +33 3 20 96 40 24<br />
Fax: +33 3 20 96 49 07<br />
Web site: www.deprezlab.fr<br />
Anti-infective drug discovery. We have developed a pl<strong>at</strong>form specialized in screening<br />
for bacterial repressor inhibitiors. Our first program has produced several series<br />
specific nanomolar, bioavailable inhibitors of EthR, a myco-bacterial repressor. In vivo,<br />
these compounds boost the activity of ethionamide, a key antibiotic used in TB. Our<br />
series has reached the level of regul<strong>at</strong>ory development. We are seeking a partnership<br />
for the development of these compounds th<strong>at</strong> have a clinical utility in the tre<strong>at</strong>ment of<br />
MDR strains of tuberculosis.<br />
62
TEXCELL<br />
Genavenir 5<br />
1 rue Pierre Fontaine<br />
91058 EVRY Cedex - FRANCE<br />
Phone: +33 1 60 91 33 10<br />
Fax: +33 1 64 93 33 24<br />
Email: ybarbier@texcell.fr<br />
Web site: www.texcell.fr<br />
Contact: Yves BARBIER<br />
Texcell is a world-renowned CSO company th<strong>at</strong> provides viral safety and immunology<br />
services in full compliance with GLP and GMP standards.<br />
Thanks to our in-depth experience of providing viral safety testing and virus valid<strong>at</strong>ion<br />
studies, we have provided support to a large number of products now licensed by<br />
the FDA, the EMEA and the MHW. Texcell is also your central lab for pre-clinical and<br />
clinical trials. We offer a dedic<strong>at</strong>ed technology pl<strong>at</strong>form in immunology. Based in<br />
France (Evry), we cre<strong>at</strong>ed in 2009 a subsidiary in USA (NY).<br />
TFCHEM<br />
Voie de l’Innov<strong>at</strong>ion - PharmaParc 2<br />
27100 VAL DE REUIL - FRANCE<br />
Phone: +33 2 32 09 01 16<br />
Fax: +33 2 32 25 07 64<br />
Email:<br />
geraldine.deliencourt@tfchemistry.com<br />
Web site: www.tfchemistry.com<br />
Contact: Géraldine<br />
DELIENCOURT-GODEFROY<br />
TFChem is a drug-discovery company, subsidiary of Sirona Biochem, which uses<br />
the fluorine <strong>at</strong>om properties to develop new glycomimetic compounds: GlycoMim ®<br />
technology.<br />
TFChem brings a unique solution to the drawbacks usually associ<strong>at</strong>ed with<br />
carbohydr<strong>at</strong>e-based drugs and unlocks the potential of sugar for the development<br />
of new, more potent and safer drugs. TFChem targets several major pharmaceutical<br />
domains but also cosmetics and biological ingredients for cells preserv<strong>at</strong>ion. TFChem<br />
is building partnerships and licensing activity with pharmaceutical and biotechnological<br />
companies.<br />
63
THERALPHA<br />
2229 route des Crêtes<br />
06560 VALBONNE SOPHIA ANTIPOLIS<br />
FRANCE<br />
Phone: +33 6 25 183 239<br />
Email: david@theralpha.com<br />
Web site: www.theralpha.com<br />
Contact: David DELLAMONICA<br />
Theralpha is a specialty pharmaceutical company focused on the development and<br />
commercializ<strong>at</strong>ion of innov<strong>at</strong>ive therapies for the tre<strong>at</strong>ment pain. Our lead product,<br />
THA903, is designed to address acute pain by sublingual administr<strong>at</strong>ion. We have<br />
three additional product candid<strong>at</strong>es in preclinical development. We are advancing<br />
next gener<strong>at</strong>ion pain drugs based on scientifically valid<strong>at</strong>ed Acid Sensing Ion Channel<br />
(ASIC) p<strong>at</strong>hways. Theralpha aims to develop its pipeline to address unmet medical<br />
need in pain, a significant economic burden. We currently have four product candid<strong>at</strong>es<br />
in development.<br />
TRANSGENE<br />
Boulevard Gonthier d’Andernach<br />
Parc d’Innov<strong>at</strong>ion - CS 80166<br />
67405 ILLKIRCH Cedex - FRANCE<br />
Phone: +33 3 88 27 91 00<br />
Fax: +33 3 88 27 91 11<br />
Email: communic<strong>at</strong>ion@transgene.fr<br />
Web site: www.transgene.fr<br />
Contact: Jean-Yves BONNEFOY<br />
Transgene is a fully integr<strong>at</strong>ed biopharmaceutical company th<strong>at</strong> designs and develops<br />
cutting-edge immunotherapeutic products to tre<strong>at</strong> cancers and chronic infectious<br />
deseases. Our expertise covers all stages of product development, from research to<br />
the manufacture of clinical b<strong>at</strong>ches, and the conducting of clinical trials.<br />
64
TROPHOS<br />
Parc Scientifique de Luminy - Case 931<br />
13288 MARSEILLE Cedex 9 - FRANCE<br />
Phone: +33 4 91 82 82 82<br />
Fax: +33 4 91 82 82 89<br />
Email: info@trophos.com<br />
Web site: www.trophos.com<br />
Contact: Damian MARRON<br />
Trophos is a l<strong>at</strong>e stage pharmaceutical company whose str<strong>at</strong>egy is to cre<strong>at</strong>e and realise value<br />
from its proprietary, innov<strong>at</strong>ive, cholesterol-oxime compound family of mitochondrial pore<br />
modul<strong>at</strong>ors by taking <strong>at</strong> least one program to clinical valid<strong>at</strong>ion for orphan/niche indic<strong>at</strong>ions<br />
in neurology and acute cardiology. Trophos lead product, olesoxime, is in an ongoing pivotal,<br />
phase 3 efficacy study in the orphan indic<strong>at</strong>ion of Amyotrophic L<strong>at</strong>eral Sclerosis (ALS) with<br />
results due fourth quarter of 2011. The study is substantially funded by a €6M EU grant<br />
(MitoTarget). The target market potential is $1Bn per annum. A second orphan indic<strong>at</strong>ion for<br />
olesoxime is SMA. A pivotal efficacy study, substantially funded by the AFM p<strong>at</strong>ient associ<strong>at</strong>ion,<br />
is ongoing with results due second half of 2013. Market potential is $200M per annum.<br />
TRO40303, Trophos’ cardiology product in the niche, acute, hospital indic<strong>at</strong>ion of cardiac IRI<br />
has successfully completed phase 1. A phase 2 POC trial will start in the second half of 2011<br />
with results due second half 2012. The study will be funded by a €6M EU grant (MitoCare).<br />
Market potential is around $500M per annum.<br />
Trophos has two str<strong>at</strong>egic deals with Actelion Ltd; an Acquisition Option Agreement and a<br />
Research Collabor<strong>at</strong>ion Agreement.<br />
VALYSCO<br />
4 place d’Ainay<br />
69002 LYON - FRANCE<br />
Phone: +33 4 72 41 09 02<br />
Fax: +33 4 72 41 08 93<br />
Email: francois.guillemin@valysco.com<br />
contact @valysco.com<br />
Web site: www.valysco.com<br />
VALYSCO is an “oper<strong>at</strong>ional consultancy organiz<strong>at</strong>ion” dedic<strong>at</strong>ed to the development<br />
of Life Sciences through the counselling of priv<strong>at</strong>e and public stake holders in human,<br />
animal, plant health and nutrition.<br />
In an intern<strong>at</strong>ional environment, VALYSCO contributes to a more efficient global &<br />
transversal development of your projects, from Research to Market , from prevention<br />
(nutrition, vaccines, diagnostics…) to tre<strong>at</strong>ment (pharmaceuticals, diagnostics…) and<br />
well being.<br />
65
VIVALIS<br />
6 rue Alain Bombard<br />
44821 SAINT HERBLAIN - FRANCE<br />
Phone: +33 2 28 07 37 10<br />
Fax: +33 2 28 07 37 11<br />
Email: info.vivalis@vivalis.com<br />
Web site: www.vivalis.com<br />
Contact: Frédéric LEGROS<br />
VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company th<strong>at</strong> provides<br />
innov<strong>at</strong>ive cell-based solutions to the pharmaceutical industry for the manufacture of<br />
vaccines and proteins and for the discovery of drugs for the prevention and tre<strong>at</strong>ment<br />
of unmet medical needs using 3 pl<strong>at</strong>forms:<br />
1) The EB66 ® Cell line used for the production of viral vaccines and monoclonal<br />
antibodies with enhanced cytotoxic activity.<br />
2) HUMALEX ® pl<strong>at</strong>form used for the discovery fully human monoclonal antibodies<br />
from human B lymphocytes.<br />
3) 3D-Screen pl<strong>at</strong>form used for identifying original molecules th<strong>at</strong> alter the threedimensional<br />
structure of a target protein.<br />
X’PROCHEM<br />
Cité scientifique<br />
Bâtiment Delamare - 4 e étage<br />
59655 VILLENEUVE D’ASCQ - FRANCE<br />
Phone: +33 3 20 43 46 69<br />
Fax: +33 3 20 43 41 75<br />
Email: reda.mhidia@gmail.fr<br />
Contact: Reda MHIDIA<br />
Chemical synthesis of proteins is an essential part of biopharmaceuticals<br />
development. X’ProChem offers a full range of custom chemical synthesis of proteins<br />
and manufacturing services to the life science and biopharmaceutical industries.<br />
Whether you are developing peptide and proteins (up to 300AA) as drug therapies,<br />
probing disease mechanisms, our science and production capability can work for you.<br />
Outsourcing your activity to X’ProChem is an efficient, cost-effective way of ensuring<br />
oper<strong>at</strong>ional productivity for your new Biopharmaceutical development through the<br />
pipeline.<br />
66
ZOPHIS<br />
5 rue de la Baume<br />
75008 PARIS - FRANCE<br />
Phone: +33 6 73 69 12 73<br />
Email: f.miceli@zophis.com<br />
Contact: François MICELI<br />
Acquisition and in-licensing of preclinical stage baccine development projects.<br />
67
BIOTECHNOLOGY AND<br />
RELATED SPECIALITIES<br />
AUTOIMMUNE THERAPIES<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Eveon<br />
PX'Therapeutics<br />
Atlanpole Biotherapies FLAMEL Technologies TcL Pharma<br />
Cabinet Regimbeau<br />
Innobiochips<br />
ERYTech Pharma<br />
Lyonbiopole<br />
BIOTECHNOLOGY COMPANY<br />
acCInov DBV Technologies Nokad<br />
Affilogic Domain Therapeutics Novalix<br />
Alaxia ERYTech Pharma Oncodesign<br />
Alize Pharma Eveon Oncomedics<br />
Animascope FLAMEL Technologies Oroxcell<br />
ANS Biotech genOway Pharmaxon<br />
Ariana Pharmaceuticals Genticel PhenoPro<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Hemarina<br />
Polyplus-transfection<br />
Atlanpole Biotherapies HTL Biotechnology Poxel<br />
Auvergne Biocluster ICDD PX’Therapeutics<br />
BioFilm Control In-Cell-Art Rhenovia Pharma<br />
Bio-Modeling Systems InGen BioSciences Synthelis<br />
Biopôle Clermont-Limagne Innobiochips TcL Pharma<br />
Cabinet Regimbeau Institut Merieux Texcell<br />
Capbiotek LFB Theralpha<br />
Cellectis Bioresearch Lyonbiopole Transgène<br />
Chel<strong>at</strong>ec Magnisense Vivalis<br />
Ciloa Metabrain Research X'ProChem<br />
Colcom MilleGen Zophis<br />
CRITT Santé Bretagne<br />
Netris Pharma<br />
CELL BIOLOGY<br />
acCInov Cabinet Regimbeau ICDD<br />
Almetis Cancer-Bio-Santé Medicen Paris Region<br />
Animascope Capbiotek Oncomedics<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
CRITT Santé Bretagne Oroxcell<br />
Atlanpole Biotherapies Domain Therapeutics Polyplus-transfection<br />
CYTOLOGY<br />
acCInov Cabinet Regimbeau CRITT Santé Bretagne<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Capbiotek<br />
Oncomedics<br />
DEVICES<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
DBV Technologies Magnisense<br />
Cabinet Regimbeau Eveon Medicen Paris Region<br />
Cancer-Bio-Santé Innobiochips<br />
Only For Children<br />
Pharmaceuticals<br />
Capbiotek<br />
Institut Merieux<br />
Université de Lyon<br />
Lyon Science Transfert<br />
CRITT Santé Bretagne<br />
Lyonbiopole
BIOTECHNOLOGY AND<br />
RELATED SPECIALITIES<br />
DIAGNOSTICS<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
CRITT Santé Bretagne Medicen Paris Region<br />
Atlanpole Biotherapies DBV Technologies Nokad<br />
BioFilm Control ICDD Oncodesign<br />
Biopôle Clermont-Limagne ImmunID Technologies Oncomedics<br />
BioSIMS Technologies InGen BioSciences PX'Therapeutics<br />
Cabinet Regimbeau Innobiochips Quinten<br />
Cancer-Bio-Santé Institut Merieux<br />
Université de Lyon<br />
Lyon Science Transfert<br />
Capbiotek<br />
Lyonbiopole<br />
Colcom<br />
Magnisense<br />
DRUG DELIVERY<br />
Animascope Capbiotek Imabiotech<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Colcom<br />
Lyonbiopole<br />
Atlanpole Biotherapies CRITT Santé Bretagne Medicen Paris Region<br />
BioFilm Control DBV Technologies Medincell<br />
Biopôle Clermont-Limagne Eveon Rhenovia Pharma<br />
Cabinet Regimbeau FLAMEL Technologies TFChem<br />
Cancer-Bio-Santé HTL Biotechnology<br />
Université de Lyon<br />
Lyon Science Transfert<br />
DRUG DISCOVERY<br />
Adocia CRITT Santé Bretagne Oncodesign<br />
Almetis<br />
Domain Therapeutics<br />
Only For Children<br />
Pharmaceuticals<br />
Animascope ERYTech Pharma Oroxcell<br />
ANS Biotech Harmonic Pharma Pharmaxon<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Imabiotech<br />
PhenoPro<br />
Atlanpole Biotherapies Lyonbiopole Prestwick Chemical<br />
Auvergne Biocluster Medicen Paris Region PX'Therapeutics<br />
Bio-Modeling Systems Medincell Quinten<br />
Biopôle Clermont-Limagne Medit Rhenovia Pharma<br />
BioSIMS Technologies Metabrain Research Roowin<br />
Cabinet Regimbeau MilleGen TB Drug Boost<br />
Cancer-Bio-Santé NicOx TcL Pharma<br />
Capbiotek<br />
Nosopharm<br />
Université de Lyon<br />
Lyon Science Transfert<br />
Colcom<br />
Novalix<br />
FOOD AND AGRICULTURE<br />
Animascope Biopôle Clermont-Limagne Capbiotek<br />
Bio-Modeling Systems Cabinet Regimbeau Institut Merieux<br />
GENE THERAPY<br />
acCInov Cabinet Regimbeau Institut Merieux<br />
Animascope Colcom Medicen Paris Region<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
CRITT Santé Bretagne PhenoPro<br />
Atlanpole Biotherapies In-Cell-Art Polyplus-transfection
BIOTECHNOLOGY AND<br />
RELATED SPECIALITIES<br />
GENOMICS<br />
Assistance Publique<br />
CRITT Santé Bretagne<br />
Hôpitaux de Paris<br />
Cabinet Regimbeau<br />
Capbiotek<br />
PhenoPro<br />
Medicen Paris Region<br />
Oncomedics<br />
IMMUNOCHEMICALS<br />
acCInov Cabinet Regimbeau Lyonbiopole<br />
Animascope FLAMEL Technologies Zophis<br />
Assistance Publique - Hôpitaux de Paris<br />
Innobiochips<br />
INDUSTRIAL AND ENVIRONMENTAL<br />
Bio-Modeling Systems Cabinet Regimbeau Eveon<br />
Biopôle Clermont-Limagne<br />
Capbiotek<br />
MOLECULAR BIOLOGY<br />
Almetis Domain Therapeutics Lyonbiopole<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Eveon<br />
Medicen Paris Region<br />
Cabinet Regimbeau ImmunID Technologies PhenoPro<br />
Capbiotek In-Cell-Art Quinten<br />
CRITT Santé Bretagne<br />
Institut Merieux<br />
PHARMACEUTICAL COMPANY<br />
Alzprotect<br />
Cabinet Regimbeau<br />
Only For Children<br />
Pharmaceuticals<br />
ANS Biotech Eveon PhenoPro<br />
Auvergne Biocluster FLAMEL Technologies Provepharm<br />
BioFilm Control Medincell Quinten<br />
Bio-Modeling Systems NicOx Trophos<br />
Biopôle Clermont-Limagne<br />
Novalix<br />
PROTEOMICS<br />
acCInov Cancer-Bio-Santé Innobiochips<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Capbiotek<br />
Lyonbiopole<br />
Atlanpole Biotherapies CRITT Santé Bretagne MEDIT<br />
Bio-Modeling Systems ICDD Oncomedics<br />
BioSIMS Technologies Imabiotech PX'Therapeutics<br />
Cabinet Regimbeau<br />
InGen BioSciences<br />
THERAPEUTICS<br />
Alize Pharma Domain Therapeutics NicOx<br />
Almetis ERYTech Pharma Nokad<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Eveon<br />
Oncodesign<br />
Bio-Modeling Systems FLAMEL Technologies<br />
Only For Children<br />
Pharmaceuticals<br />
Biopôle Clermont-Limagne Harmonic Pharma Provepharm<br />
Cabinet Regimbeau Institut Merieux PX'Therapeutics<br />
Capbiotek<br />
Lyonbiopole<br />
Université de Lyon<br />
Lyon Science Transfert<br />
CRITT Santé Bretagne Medicen Paris Region Zophis<br />
DBV Technologies<br />
Metabrain Research
EQUIPMENT<br />
AND SUPPLIES<br />
CELL/TISSUE CULTURE<br />
acCInov Harmonic Pharma Polyplus-transfection<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
ICDD<br />
Texcell<br />
Cabinet Regimbeau LFB Trophos<br />
Capbiotek<br />
Netris Pharma<br />
Colcom<br />
Oncomedics<br />
CHEMICALS AND REAGENTS<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Colcom<br />
Institut Merieux<br />
Cabinet Regimbeau Innobiochips Oxeltis<br />
CHROMATOGRAPHY<br />
acCInov Iris Pharma Trophos<br />
Cabinet Regimbeau<br />
Oxeltis<br />
Imabiotech<br />
Texcell<br />
KITS/ASSAYS/ANTIBODIES<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Cellectis Bioresearch Institut Merieux<br />
BioSIMS Technologies Colcom Magnisense<br />
Cabinet Regimbeau ICDD Netris Pharma<br />
Cancer-Bio-Santé InGen BioSciences Texcell<br />
Capbiotek<br />
Innobiochips<br />
LAB EQUIPMENT/SUPPLIER<br />
Cabinet Regimbeau InGen BioSciences Texcell<br />
Capbiotek<br />
Institut Merieux<br />
Imabiotech<br />
MEDIT<br />
Cabinet Regimbeau<br />
LIQUIDE HANDLING<br />
Eveon<br />
MEASUREMENT AND ANALITYCAL INSTRUMENTATION<br />
BioSIMS Technologies Imabiotech Oxeltis<br />
Cabinet Regimbeau<br />
Innobiochips<br />
Colcom<br />
Magnisense<br />
MICROSCOPY<br />
BioSIMS Technologies ICDD Oncomedics<br />
Cabinet Regimbeau Iris Pharma Texcell<br />
Capbiotek Netris Pharma Trophos<br />
acCInov<br />
Cabinet Regimbeau<br />
PROCESSING EQUIPMENT<br />
Capbiotek<br />
Harmonic Pharma<br />
Cabinet Regimbeau<br />
PUMPS<br />
Eveon
EQUIPMENT<br />
AND SUPPLIES<br />
SAMPLE PREPARATION<br />
Cabinet Regimbeau Imabiotech Iris Pharma<br />
Capbiotek Institut Merieux Oncomedics<br />
SCALES<br />
Cabinet Regimbeau<br />
SPECTROSCOPY<br />
BioSIMS Technologies Cabinet Regimbeau Imabiotech<br />
VACCUM TECHNOLOGY<br />
Cabinet Regimbeau<br />
SCIENTIFIC, RESEARCH<br />
AND CONTRACT SERVICES<br />
ACCREDIDATION AND CERTIFICATION SERVICES<br />
Atlanpole Biotherapies Eveon Oroxcell<br />
BIOPROCESSING AND CHEMICAL PRODUCTION<br />
acCInov Colcom X’ProChem<br />
Atlanpole Biotherapies<br />
Capbiotek<br />
Institut Merieux<br />
Synthelis<br />
CLINICAL AND REGULATORY SERVICES<br />
acCInov Avogadro Iris Pharma<br />
Am<strong>at</strong>si<br />
Biotrial<br />
Only For Children<br />
Pharmaceuticals<br />
Analgesia Partnership Capbiotek Texcell<br />
Assistance Publique - Hôpitaux de Paris<br />
Eveon<br />
Atlanpole Biotherapies<br />
ImmunID Technologies<br />
CONTRACT MANUFACTURING<br />
acCInov Cancer-Bio-Santé Roowin<br />
Am<strong>at</strong>si Colcom Vivalis<br />
Analgesia Partnership Eveon X'ProChem<br />
Atlanpole Biotherapies Oxeltis<br />
Avogadro<br />
PX’Therapeutics<br />
CONTRACT RESEARCH<br />
Aepodia Chel<strong>at</strong>ec Neurofit<br />
Am<strong>at</strong>si Ciloa Nosopharm<br />
Analgesia Partnership Colcom Novalix<br />
Animascope Eurofins Optimed Oncomedics<br />
ANS Biotech<br />
Eveon<br />
Only For Children<br />
Pharmaceuticals<br />
Atlanpole Biotherapies genOway Oroxcell<br />
Atlantic Bone Screen Harmonic Pharma Oxeltis<br />
Auvergne Biocluster ICDD PhenoPro<br />
Avogadro Imabiotech Porsolt<br />
Bio-Modeling Systems In-Cell-Art Prestwick Chemical<br />
BioSIMS Technologies InGen BioSciences Provepharm<br />
Biotrial Innobiochips Rhenovia Pharma<br />
Cabinet Regimbeau Iris Pharma Roowin<br />
Cancer-Bio-Santé<br />
MEDIT<br />
Capbiotek<br />
Metabrain Research
SCIENTIFIC, RESEARCH<br />
AND CONTRACT SERVICES<br />
LABORATORY, ANALITYCAL AND TESTING SERVICES<br />
acCInov Imabiotech Oncomedics<br />
Am<strong>at</strong>si ImmunID Technologies Provepharm<br />
Analgesia Partnership In-Cell-Art PX'Therapeutics<br />
Atlanpole Biotherapies Innobiochips Quinten<br />
Atlantic Bone Screen Iris Pharma Roowin<br />
Avogadro Labor<strong>at</strong>oire ICARE Texcell<br />
Cancer-Bio-Santé<br />
Capbiotek<br />
Neurofit<br />
Oncodesign<br />
RESEARCH ORGANIzATION/INSTITUTE<br />
Analgesia Partnership CRITT Santé Bretagne Provepharm<br />
Assistance Publique<br />
Hôpitaux de Paris<br />
Eveon<br />
Quinten<br />
Atlanpole Biotherapies GELARC Roowin<br />
Cancer-Bio-Santé Institut Merieux TB Drug Boost<br />
Canceropole CLARA Neurofit Trophos<br />
Capbiotek<br />
PhenoPro<br />
OTHER<br />
Science Park<br />
Heuristic Systems biology ;<br />
Heuristic Integr<strong>at</strong>ive Biology<br />
Genome engineering<br />
Business Intelligence Reporting<br />
and Analytics<br />
Vaccines<br />
Drug repositioning or repurposing<br />
Dynamic system biology<br />
IVD tests development<br />
Technology provider<br />
Software vendor, Bio-cheminform<strong>at</strong>ics,<br />
drug design, molecular modeling,<br />
biostructure<br />
Preclinical services<br />
R&D for genes<br />
and oligonucleotides delivery<br />
Consulting<br />
Biocitech<br />
Bio-Modeling Systems<br />
Cellectis Bioresearch<br />
ClicD<strong>at</strong>a<br />
Genticel<br />
Harmonic Pharma<br />
Helios Biosciences<br />
InGen BioSciences<br />
Kayentis<br />
MEDIT<br />
Neurofit<br />
Polyplus-transfection<br />
Valysco
NOTES<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NOTES<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .<br />
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The <strong>French</strong> particip<strong>at</strong>ion<br />
is organized by<br />
<strong>UBIFRANCE</strong><br />
The <strong>French</strong> Agency for Intern<strong>at</strong>ional<br />
Business Development<br />
Head Office in Paris<br />
77 boulevard Saint-Jacques<br />
75014 PARIS - FRANCE<br />
Contact: Malika HACHEMI<br />
Phone: +33 1 40 73 35 70<br />
Fax: +33 1 40 73 32 02<br />
Email: malika.hachemi@ubifrance.fr<br />
Web site: www.ubifrance.fr<br />
Contacts in USA<br />
San Francisco - Mr Benoit COLINOT<br />
88 Kearny Street - Suite 700<br />
CA 94108 SAN FRANCISCO<br />
Phone: +1 415 568 4566<br />
Email: benoit.colinot@ubifrance.fr<br />
Web: www.ubifrance.fr
Change language